Author: "De Luca, Andrea (ORCID:0000-0002-8311-6935)" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"De Luca, Andrea (ORCID:0000-0002-8311-6935)"' showing total 207 results

Start Over Author "De Luca, Andrea (ORCID:0000-0002-8311-6935)"

207 results on '"De Luca, Andrea (ORCID:0000-0002-8311-6935)"'

1. Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy

Author: Dragoni, Filippo, Rossetti, Barbara, Lombardi, Francesca, Raffaelli, Chiara Spertilli, Bartolini, Niccolò, Giammarino, Federica, Moschese, Davide, Di Giambenedetto, Simona, Fabbiani, Massimiliano, De Luca, Andrea, Vicenti, Ilaria, Zazzi, Maurizio, Saladini, Francesco, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), De Luca, Andrea (ORCID:0000-0002-8311-6935), Dragoni, Filippo, Rossetti, Barbara, Lombardi, Francesca, Raffaelli, Chiara Spertilli, Bartolini, Niccolò, Giammarino, Federica, Moschese, Davide, Di Giambenedetto, Simona, Fabbiani, Massimiliano, De Luca, Andrea, Vicenti, Ilaria, Zazzi, Maurizio, Saladini, Francesco, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Published: 2022

2. Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults

Author: Rossetti, Barbara, Lombardi, Francesca, Belmonti, Simone, D'Andrea, Marco Maria, Tordini, Giacinta, D'Avino, Alessandro, Borghetti, Alberto, Moschese, Davide, De Luca, Andrea, Montagnani, Francesca, Lombardi, Francesca (ORCID:0000-0001-5757-8346), De Luca, Andrea (ORCID:0000-0002-8311-6935), Rossetti, Barbara, Lombardi, Francesca, Belmonti, Simone, D'Andrea, Marco Maria, Tordini, Giacinta, D'Avino, Alessandro, Borghetti, Alberto, Moschese, Davide, De Luca, Andrea, Montagnani, Francesca, Lombardi, Francesca (ORCID:0000-0001-5757-8346), and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Published: 2019

3. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

Author: Ascione, Antonio, De Luca, Massimo, Melazzini, Mario, Montilla, Simona, Trotta, Maria Paola, Petta, Salvatore, Puoti, Massimo, Sangiovanni, Vincenzo, Messina, Vincenzo, Bruno, Savino, Izzi, Antonio, Villa, Erica, Aghemo, Alessio, Zignego, Anna Linda, Orlandini, Alessandra, Fontanella, Luca, Gasbarrini, Antonio, Marzioni, Marco, Giannini, Edoardo G., Craxì, Antonio, Abbati, Giuseppe, Alberti, Alfredo, Andreone, Pietro, Andreoni, Massimo, Angeli, Paolo, Angelico, Mario, Angarano, Gioacchino, Angrisani, Debora, Antinori, Andrea, Antonini, Cinzia, Avancini, Ivo, Barone, Michele, Bruno, Raffaele, Benedetti, Antonio, Bernabucci, Veronica, Blanc, Pier, Boarini, Chiara, Boffa, Nicola, Boglione, Lucio, Borghi, Vanni, Borgia, Guglielmo, Brancaccio, Giuseppina, Brunetto, Maurizia, Cacciola, Irene, Calabrese, Paolo, Calvaruso, Vincenza, Campagnolo, Davide, Canovari, Benedetta, Caporaso, Nicola, Capra, Franco, Carolo, Giada, Cassola, Giovanni, Castelli, Francesco, Cauda, Roberto, Silberstein, Francesca Ceccherini, Cecere, Roberto, Chessa, Luchino, Chiodera, Alessandro, Chirianni, Antonio, Ciancio, Alessia, Cima, Serena, Coco, Barbara, Colombo, Massimo, Coppola, Nicola, Corti, Giampaolo, Cosco, Lucio, Corradori, Silvia, Cozzolongo, Raffaele, Cristaudo, Antonio, Danieli, Elena, Monforte, Antonella D’Arminio, Monache, Marco delle, Del Poggio, Paolo, de Luca, Andrea, Dentone, Chiara, Di Biagio, Antonio, Di Leo, Alfredo, Di Perri, Giovanni, Di Stefano, Marco, D’Offizi, Giampiero, Donato, Francesca, Durante, Emanuele, Erne, Elke, Fagiuoli, Stefano, Falasca, Katia, Federico, Alessandro, Felder, Martina, Ferrari, Carlo, Gaeta, Giovanni Battista, Ganga, Roberto, Gatti, Pietro, Giacomet, Vania, Giacometti, Andrea, Gianstefani, Alice, Giordani, Maria, Giorgini, Alessia, Grieco, Antonio, Guerra, Michele, Gulminetti, Roberto, Ieluzzi, Donatella, Imparato, Michele, Iodice, Valentina, La Monica, Silvia, Lazzarin, Adriano, Lenzi, Marco, Levrero, Massimo, Lichtner, Myriam, Lionetti, Raffaella, Guercio, Carmela Lo, Madonna, Salvatore, Magnani, Silvia, Maida, Ivana, Marignani, Massimo, Marrone, Aldo, Marsetti, Fabio, Martini, Silvia, Masarone, Mario, Maserati, Renato, Mastroianni, Claudio Maria, Memoli, Massimo, Menzaghi, Barbara, Merli, Manuela, Miele, Luca, Milella, Michele, Mondelli, Mario, Montalbano, Marzia, Monti, Monica, Morelli, Olivia, Morisco, Filomena, Nardone, Gaetano, Novara, Sergio, Onnelli, Giovanna, Onofrio, Mirella, Paganin, Simona, Pani, Luca, Parisi, Maria Rita, Parruti, Giustino, Pasquazzi, Caterina, Pasulo, Luisa, Perno, Carlo Federico, Persico, Marcello, Piai, Guido, Picciotto, Antonino, Pigozzi, Grazielle Marie, Piovesan, Sara, Piras, Maria Chiara, Pirisi, Massimo, Piscaglia, Anna Maria, Ponti, Laura, Potenza, Domenico, Pravadelli, Cecilia, Quartini, Mariano, Quirino, Tiziana, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Rendina, Maria, Rizzardini, Giuliano, Rizzetto, Mario, Rizzo, Salvatore, Romagnoli, Dante, Romano, Antonietta, Rossi, Cristina, Rumi, Maria Grazia, Russello, Maurizio, Russo, Francesca Paolo, Russo, Maria Luisa, Sansonno, Domenico Ettore, Santantonio, Teresa Antonia, Saracco, Giorgio, Schimizzi, Anna Maria, Serviddio, Gaetano, Simeone, Filomena, Solinas, Attilio, Soria, Alessandro, Tabone, Marco, Taliani, Gloria, Tarantino, Giuseppe, Tarquini, Pierluigi, Tavio, Marcello, Termite, Antonio, Teti, Elisabetta, Toniutto, Pierluigi, Torti, Carlo, Tundi, Paolo, Vecchiet, Giacomo, Verucchi, Gabriella, Gentilucci, Umberto Vespasiani, Vinci, Maria, Vullo, Vincenzo, Zolfino, Teresa, Zuin, Massimo, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Cauda, Roberto (ORCID:0000-0002-1498-4229), de Luca, Andrea (ORCID:0000-0002-8311-6935), Grieco, Antonio (ORCID:0000-0002-0544-8993), Miele, Luca (ORCID:0000-0003-3464-0068), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Ascione, Antonio, De Luca, Massimo, Melazzini, Mario, Montilla, Simona, Trotta, Maria Paola, Petta, Salvatore, Puoti, Massimo, Sangiovanni, Vincenzo, Messina, Vincenzo, Bruno, Savino, Izzi, Antonio, Villa, Erica, Aghemo, Alessio, Zignego, Anna Linda, Orlandini, Alessandra, Fontanella, Luca, Gasbarrini, Antonio, Marzioni, Marco, Giannini, Edoardo G., Craxì, Antonio, Abbati, Giuseppe, Alberti, Alfredo, Andreone, Pietro, Andreoni, Massimo, Angeli, Paolo, Angelico, Mario, Angarano, Gioacchino, Angrisani, Debora, Antinori, Andrea, Antonini, Cinzia, Avancini, Ivo, Barone, Michele, Bruno, Raffaele, Benedetti, Antonio, Bernabucci, Veronica, Blanc, Pier, Boarini, Chiara, Boffa, Nicola, Boglione, Lucio, Borghi, Vanni, Borgia, Guglielmo, Brancaccio, Giuseppina, Brunetto, Maurizia, Cacciola, Irene, Calabrese, Paolo, Calvaruso, Vincenza, Campagnolo, Davide, Canovari, Benedetta, Caporaso, Nicola, Capra, Franco, Carolo, Giada, Cassola, Giovanni, Castelli, Francesco, Cauda, Roberto, Silberstein, Francesca Ceccherini, Cecere, Roberto, Chessa, Luchino, Chiodera, Alessandro, Chirianni, Antonio, Ciancio, Alessia, Cima, Serena, Coco, Barbara, Colombo, Massimo, Coppola, Nicola, Corti, Giampaolo, Cosco, Lucio, Corradori, Silvia, Cozzolongo, Raffaele, Cristaudo, Antonio, Danieli, Elena, Monforte, Antonella D’Arminio, Monache, Marco delle, Del Poggio, Paolo, de Luca, Andrea, Dentone, Chiara, Di Biagio, Antonio, Di Leo, Alfredo, Di Perri, Giovanni, Di Stefano, Marco, D’Offizi, Giampiero, Donato, Francesca, Durante, Emanuele, Erne, Elke, Fagiuoli, Stefano, Falasca, Katia, Federico, Alessandro, Felder, Martina, Ferrari, Carlo, Gaeta, Giovanni Battista, Ganga, Roberto, Gatti, Pietro, Giacomet, Vania, Giacometti, Andrea, Gianstefani, Alice, Giordani, Maria, Giorgini, Alessia, Grieco, Antonio, Guerra, Michele, Gulminetti, Roberto, Ieluzzi, Donatella, Imparato, Michele, Iodice, Valentina, La Monica, Silvia, Lazzarin, Adriano, Lenzi, Marco, Levrero, Massimo, Lichtner, Myriam, Lionetti, Raffaella, Guercio, Carmela Lo, Madonna, Salvatore, Magnani, Silvia, Maida, Ivana, Marignani, Massimo, Marrone, Aldo, Marsetti, Fabio, Martini, Silvia, Masarone, Mario, Maserati, Renato, Mastroianni, Claudio Maria, Memoli, Massimo, Menzaghi, Barbara, Merli, Manuela, Miele, Luca, Milella, Michele, Mondelli, Mario, Montalbano, Marzia, Monti, Monica, Morelli, Olivia, Morisco, Filomena, Nardone, Gaetano, Novara, Sergio, Onnelli, Giovanna, Onofrio, Mirella, Paganin, Simona, Pani, Luca, Parisi, Maria Rita, Parruti, Giustino, Pasquazzi, Caterina, Pasulo, Luisa, Perno, Carlo Federico, Persico, Marcello, Piai, Guido, Picciotto, Antonino, Pigozzi, Grazielle Marie, Piovesan, Sara, Piras, Maria Chiara, Pirisi, Massimo, Piscaglia, Anna Maria, Ponti, Laura, Potenza, Domenico, Pravadelli, Cecilia, Quartini, Mariano, Quirino, Tiziana, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Rendina, Maria, Rizzardini, Giuliano, Rizzetto, Mario, Rizzo, Salvatore, Romagnoli, Dante, Romano, Antonietta, Rossi, Cristina, Rumi, Maria Grazia, Russello, Maurizio, Russo, Francesca Paolo, Russo, Maria Luisa, Sansonno, Domenico Ettore, Santantonio, Teresa Antonia, Saracco, Giorgio, Schimizzi, Anna Maria, Serviddio, Gaetano, Simeone, Filomena, Solinas, Attilio, Soria, Alessandro, Tabone, Marco, Taliani, Gloria, Tarantino, Giuseppe, Tarquini, Pierluigi, Tavio, Marcello, Termite, Antonio, Teti, Elisabetta, Toniutto, Pierluigi, Torti, Carlo, Tundi, Paolo, Vecchiet, Giacomo, Verucchi, Gabriella, Gentilucci, Umberto Vespasiani, Vinci, Maria, Vullo, Vincenzo, Zolfino, Teresa, Zuin, Massimo, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Cauda, Roberto (ORCID:0000-0002-1498-4229), de Luca, Andrea (ORCID:0000-0002-8311-6935), Grieco, Antonio (ORCID:0000-0002-0544-8993), Miele, Luca (ORCID:0000-0003-3464-0068), and Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X)
Abstract: Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12 weeks after the end of treatment (SVR12). Results: Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5 g/dL (OR 2.04: 95% CI 1.0–4.2, p < 0.05) and hypertension (OR 4.6: 95% CI 2.3–9.2, p < 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2 mg/dL (OR 4.9: 95% CI 1.17–20.71, p = 0.029) as the only variable independently associated with SVR12. Conclusion: Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.
Published: 2018

4. The effect of primary drug resistance on CD4 cell decline and the viral load set-point in HIV positive individuals before the start of antiretroviral therapy

Author: Schultze, Anna, Torti, Carlo, Cozzi-Lepri, Alessandro, Vandamme, Anne-Mieke, Zazzi, Maurizio, Sambatakou, Helen, De Luca, Andrea, Geretti, Anna Maria, Sonnerborg, Ander, Ruiz, Lidia, Monno, Laura, Di Giambenedetto, Simona, Gori, Andrea, Lapadula, Giuseppe, De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Schultze, Anna, Torti, Carlo, Cozzi-Lepri, Alessandro, Vandamme, Anne-Mieke, Zazzi, Maurizio, Sambatakou, Helen, De Luca, Andrea, Geretti, Anna Maria, Sonnerborg, Ander, Ruiz, Lidia, Monno, Laura, Di Giambenedetto, Simona, Gori, Andrea, Lapadula, Giuseppe, De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: OBJECTIVE: To evaluate the effect of primary resistance and selected polymorphic amino-acid substitutions in HIV reverse transcriptase (RT) and protease (PR) on the CD4 count and viral load (VL) set point before the start of ART. DESIGN: Prospective cohort study. METHODS: 6,180 individuals with a resistance test prior to starting ART accessing care in HIV clinics across Europe who had at least 1 VL and 1 CD4 test available were included in the analysis. The impact of amino-acid substitutions variants on VL and CD4 trends was investigated using linear mixed models. Clusters of mutations were studied using principal component analysis. RESULTS: Overall, the detection of any primary resistance was not associated with either the speed of CD4 decline or the viral load set point. However, transmitted nucleoside RT inhibitor and PR inhibitor resistance appeared to be weakly associated with lower VL set points, as were the polymorphic G16E or Q92K PR mutations. There was some evidence suggesting that these effects varied according to HIV subtype, with the effects of transmitted NRTI and PR resistance being particularly marked among individuals with a subtype B virus. A cluster of five polymorphic PR substitutions at position 20, 13, 36, 69 and 89 was associated with less steep CD4 declines and lower VL set points. CONCLUSIONS: Although we found little evidence for an association between primary resistance and CD4 speed of decline and VL set point, the potential role of polymorphic PR (alone or in clusters) and their interplay with HIV subtype needs to be further evaluated.
Published: 2018

5. HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART

Author: Lombardi, Francesca, Belmonti, Simone, Rapone, Lucrezia, Borghetti, Alberto, Ciccullo, Arturo, Gagliardini, Roberta, Baldin, Gianmaria, Montagnani, Francesca, Moschese, Davide, Emiliozzi, Arianna, Rossetti, Barbara, De Luca, Andrea, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Lombardi, Francesca, Belmonti, Simone, Rapone, Lucrezia, Borghetti, Alberto, Ciccullo, Arturo, Gagliardini, Roberta, Baldin, Gianmaria, Montagnani, Francesca, Moschese, Davide, Emiliozzi, Arianna, Rossetti, Barbara, De Luca, Andrea, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: Background: The influence of HIV-1 co-receptor usage on the course of therapy in subjects fully responding to ART has been poorly investigated. Objectives: To explore the relationship between co-receptor tropism and cellular reservoir size, residual viremia and subsequent virological outcome in ART-treated patients with HIV-1 RNA stable <50 copies/mL. Study design: Viral co-receptor usage was predicted by viral env DNA sequencing with geno2pheno interpretation (FPR20%) and classified as R5 and non-R5. Total blood-associated HIV-1 DNA levels (log10 copies/106 leukocytes) were measured by qRT-PCR (5′LTR). Residual plasma viremia was categorized as detectable (1–49 cps/mL) or undetectable (<1 copy/mL). Virological rebounds (any HIV-1 RNA >50 copies/mL) were evaluated over 96 weeks. Results: The study included 116 subjects. Patients with R5 virus (n = 59) and non-R5 virus (n = 57) were homogeneous for the main characteristics except for the lower nadir CD4 cell count in the non-R5 group. Patients with non-R5 variants showed higher levels of HIV-1 DNA as compared to patients with R5 virus: mean 2.47 (95% CI 2.37–2.56) vs 2.17 (2.08–2.26) (p < 0.001). Moreover, a higher proportion of patients in the non-R5 group displayed detectable residual viremia with respect to the R5-group (54.4% vs 32.2%, p =.016). Detectable residual viremia was found to be significantly associated with viral rebounds. Conclusion: The presence of non-R5 viral DNA variants is related to a higher probability of residual viremia and to a larger size of the cellular viral reservoir in this setting. These data highlight a potential role of viral tropism in the monitoring of HIV-1 infection in virologically controlled subject.
Published: 2018

6. Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study

Author: Gagliardini, Roberta, Ciccullo, Arturo, Borghetti, Alberto, Maggiolo, Franco, Bartolozzi, Dario, Borghi, Vanni, Pecorari, Monica, Di Biagio, Antonio, Callegaro, Anna Paola, Bruzzone, Bianca, Saladini, Francesco, Paolucci, Stefania, Maserati, Renato, Zazzi, Maurizio, Di Giambenedetto, Simona, De Luca, Andrea, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), De Luca, Andrea (ORCID:0000-0002-8311-6935), Gagliardini, Roberta, Ciccullo, Arturo, Borghetti, Alberto, Maggiolo, Franco, Bartolozzi, Dario, Borghi, Vanni, Pecorari, Monica, Di Biagio, Antonio, Callegaro, Anna Paola, Bruzzone, Bianca, Saladini, Francesco, Paolucci, Stefania, Maserati, Renato, Zazzi, Maurizio, Di Giambenedetto, Simona, De Luca, Andrea, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Background. Dual therapy (DT) with boosted protease inhibitors (bPIs) plus lamivudine has been shown to be superior to bPI monotherapy in virologically suppressed patients despite previous selection of the lamivudine resistance M184V mutation. We compared the virological efficacy of lamivudine-based DT in patients with and without a history of M184V detection. Methods. We retrospectively analyzed patients with HIV-RNA ≤50 copies/mL switching to DT with at least 1 previous resistance genotype in the ARCA database. Time to virological failure (VF; HIV-RNA ≥200 copies/mL or 2 consecutive HIV-RNA >50 copies/mL) and to treatment discontinuation (TD) was analyzed by survival analysis. Results. Four hundred thirty-six patients switching to lamivudine plus bPIs (70%) or integrase inhibitors (30%) were included. Patients with M184V (n = 87) were older, had lower nadir CD4+ cell count, longer duration of antiretroviral therapy and of virologic suppression, and higher rate of hepatitis C virus infection compared with patients without M184V. The 3-year probability of remaining free from VF was 91.9% (95% confidence interval [CI], 86.6-97.2) without M184V and 87.8% (95% CI, 78.4-97.2) with M184V (P = .323). The time to TD did not differ between groups. Multivariate analysis adjusting for baseline variables differing between groups also did not detect M184V as being associated with VF or TD; however, the 3-year probability of remaining free of viral blips (isolated HIV-RNA 51-199 copies/mL) was 79.8% (95% CI, 67.8%-91.8%) with M184V vs 90.1% (95% CI, 84.0%-96.2%) without M184V (P = .016). Conclusions. Previous selection of M184V did not increase the risk of VF or TD with lamivudine-based DT but was associated with a higher probability of viral blips.
Published: 2018

7. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients

Author: Ciccullo, Arturo, Baldin, Gianmaria, Capetti, Amedeo, Rusconi, Stefano, Sterrantino, Gaetana, D'Ettorre, Gabriella, Colafigli, Manuela, Modica, Sara, Lagi, Filippo, Giacomelli, Andrea, Cossu, Maria Vittoria, Restelli, Sibilla, De Luca, Andrea, Di Giambenedetto, Simona, De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Ciccullo, Arturo, Baldin, Gianmaria, Capetti, Amedeo, Rusconi, Stefano, Sterrantino, Gaetana, D'Ettorre, Gabriella, Colafigli, Manuela, Modica, Sara, Lagi, Filippo, Giacomelli, Andrea, Cossu, Maria Vittoria, Restelli, Sibilla, De Luca, Andrea, Di Giambenedetto, Simona, De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: BACKGROUND: Two-drug regimens are increasingly used in clinical practice as switch strategies. We compared the efficacy and safety of two dolutegravir-based dual therapies (DT): dolutegravir plus lamivudine (3TC group) versus DTG plus rilpivirine (RPV group). METHODS: In a multicenter cohort of virologically suppressed (HIV-RNA <50 cp/ml) HIV+ pts switching to DTG+3TC or DTG+RPV we analyzed the incidence of virological failures (VF) and treatment discontinuations (TD), as well as their predictors. RESULTS: We analyzed 416 pts, 229 in the 3TC group and 187 in the RPV group. The 3TC group, during 344.4 person-years of follow-up (PYFU), had 10 VF without the emergence of resistance mutations, while 30 pts discontinued the regimen. In the RPV group, during 371.0 PYFU, there were 5 VF (one developed NNRTI-mutations Y181C and E138Q) and 13 TD. The estimated probability of remaining free from VF at 48 weeks showed no significant difference between groups (log-rank 0.172). We found a higher risk of VF in patients with peak VL>500000cp/ml in both treatment groups (log-rank p=0.004 in each group). The estimated probability of remaining in the study regimen at week 48 was 89.0% with DTG+3TC and 96.1% with DTG+RPV (log-rank 0.015). After adjusting for potential confounders, treatment group was not associated to TD. A significant decrease in total cholesterol was observed at week 48 in both groups while renal function remained unchanged. CONCLUSIONS: DTG+RPV and DTG+3TC were compared in populations with different characteristics in clinical practice: both regimens showed good effectiveness and improved lipid profile.
Published: 2018

8. Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study

Author: Leone, Sebastiano, Shanyinde, Milensu, Cozzi Lepri, Alessandro, Lampe, Fiona C., Caramello, Pietro, Costantini, Andrea, Giacometti, Andrea, De Luca, Andrea, Cingolani, Antonella, Ceccherini Silberstein, Francesca, Puoti, Massimo, Gori, Andrea, d’Arminio Monforte, Antonella, De Luca, Andrea (ORCID:0000-0002-8311-6935), Cingolani, Antonella (ORCID:0000-0002-3793-2755), Leone, Sebastiano, Shanyinde, Milensu, Cozzi Lepri, Alessandro, Lampe, Fiona C., Caramello, Pietro, Costantini, Andrea, Giacometti, Andrea, De Luca, Andrea, Cingolani, Antonella, Ceccherini Silberstein, Francesca, Puoti, Massimo, Gori, Andrea, d’Arminio Monforte, Antonella, De Luca, Andrea (ORCID:0000-0002-8311-6935), and Cingolani, Antonella (ORCID:0000-0002-3793-2755)
Abstract: To evaluate incidence rates of and predictors for any antiretroviral (ART) drug discontinuation by HCV infection status in a large Italian cohort of HIV infected patients. All patients enrolled in ICONA who started combination antiretroviral therapy (cART) containing abacavir or tenofovir or emtricitabine or lamivudine plus efavirenz or rilpivirine or atazanavir/r or darunavir/r (DRV/r) or lopinavir/r or dolutegravir or elvitegravir or raltegravir were included. Multivariate Poisson regression models were used to determine factors independently associated with single ART drug discontinuation. Inverse probability weighting method to control for potential informative censoring was applied. Data from 10,637 patients were analyzed and 1,030 (9.7%) were HCV-Ab positive. Overall, there were 15,464 ART discontinuations due to any reason in 82,415.9 person-years of follow-up (PYFU) for an incidence rate (IR) of 18.8 (95% confidence interval [95%CI] 18.5–19.1) per 100 PYFU. No difference in IR of ART discontinuation due to any reason between HCV-infected and -uninfected patients was found. In a multivariable Poisson regression model, HCV-infected participants were at higher risk of darunavir/r discontinuation due to any reason (adjusted incidence rate ratio = 1.5, 95%CI 1.01–2.22, p value = 0.045) independently of demographics, HIV-related, ART and life-style factors. Among DRV/r treated patients, we found that HCV-viremic patients had twice the risk of ART discontinuation due to any reason than HCV-aviremic patients. In conclusion, HIV/HCV coinfected patients had a marginal risk increase of DRV/r discontinuation due to any reason compared with those without coinfection.
Published: 2018

9. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study

Author: Gagliardini, Roberta, Ciccullo, Arturo, Borghetti, Alberto, Maggiolo, Franco, Bartolozzi, Dario, Borghi, Vanni, Pecorari, Monica, Di Biagio, Antonio, Callegaro, Anna Paola, Bruzzone, Bianca, Saladini, Francesco, Paolucci, Stefania, Maserati, Renato, Zazzi, Maurizio, Di Giambenedetto, Simona, De Luca, Andrea, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), De Luca, Andrea (ORCID:0000-0002-8311-6935), Gagliardini, Roberta, Ciccullo, Arturo, Borghetti, Alberto, Maggiolo, Franco, Bartolozzi, Dario, Borghi, Vanni, Pecorari, Monica, Di Biagio, Antonio, Callegaro, Anna Paola, Bruzzone, Bianca, Saladini, Francesco, Paolucci, Stefania, Maserati, Renato, Zazzi, Maurizio, Di Giambenedetto, Simona, De Luca, Andrea, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: not available
Published: 2018

10. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial

Author: Fabbiani, Massimiliano, Gagliardini, Roberta, Ciccarelli, Nicoletta, Quiros Roldan, Eugenia, Latini, Alessandra, D'Ettorre, Gabriella, Antinori, Andrea, Castagna, Antonella, Orofino, Giancarlo, Francisci, Daniela, Chinello, Pierangelo, Madeddu, Giordano, Grima, Pierfrancesco, Rusconi, Stefano, Del Pin, Barbara, Lombardi, Francesca, D'Avino, Alessandro, Focà, Emanuele, Colafigli, Manuela, Cauda, Roberto, Di Giambenedetto, Simona, De Luca, Andrea, Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), Lombardi, Francesca (ORCID:0000-0001-5757-8346), Cauda, Roberto (ORCID:0000-0002-1498-4229), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), De Luca, Andrea (ORCID:0000-0002-8311-6935), Fabbiani, Massimiliano, Gagliardini, Roberta, Ciccarelli, Nicoletta, Quiros Roldan, Eugenia, Latini, Alessandra, D'Ettorre, Gabriella, Antinori, Andrea, Castagna, Antonella, Orofino, Giancarlo, Francisci, Daniela, Chinello, Pierangelo, Madeddu, Giordano, Grima, Pierfrancesco, Rusconi, Stefano, Del Pin, Barbara, Lombardi, Francesca, D'Avino, Alessandro, Focà, Emanuele, Colafigli, Manuela, Cauda, Roberto, Di Giambenedetto, Simona, De Luca, Andrea, Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), Lombardi, Francesca (ORCID:0000-0001-5757-8346), Cauda, Roberto (ORCID:0000-0002-1498-4229), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Objectives: To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ritonavir + lamivudine versus continuing a standard regimen with atazanavir/ritonavir + 2NRTI in virologically suppressed patients. Methods: ATLAS-M is a 96 week open-label, randomized, non-inferiority (margin -12%) trial enrolling HIV-infected adults on atazanavir/ritonavir + 2NRTI, with stable HIV-RNA <50 copies/mL and CD4 counts >200 cells/mm3. At baseline, patients were randomized 1:1 to switch to atazanavir/ritonavir + lamivudine or to continue the previous regimen. Here, we report the 96 week efficacy and safety data. The study was registered with ClinicalTrials.gov, number NCT01599364. Results: Overall, 266 subjects were enrolled (133 in each arm). At 96 weeks, in the ITT population, patients free of treatment failure totalled 103 (77.4%) with atazanavir/ritonavir + lamivudine and 87 (65.4%) with triple therapy (difference +12.0%, 95% CI +1.2/+22.8, P = 0.030), demonstrating the superiority of dual therapy. Two (1.5%) and 9 (6.8%) virological failures occurred in the dual-therapy arm and the triple-therapy arm, respectively, without development of resistance to any study drug. Clinical adverse events occurred at similar rates in both arms. A higher frequency of grade 3-4 hyperbilirubinemia (66.9% versus 50.4%, P = 0.006) and hypertriglyceridaemia (6.8% versus 1.5%, P = 0.031) occurred with dual therapy, although this never led to treatment discontinuation. A significant improvement in renal function and lumbar spine bone mineral density occurred in the dual-therapy arm. The evolution of CD4, HIV-DNA levels and neurocognitive performance was similar in both arms. Conclusions: In this randomized study, a treatment switch to atazanavir/ritonavir + lamivudine was superior over the continuation of atazanavir/ritonavir + 2NRTI in virologically suppressed patients, with a sustained benefit in terms of improved renal function and bone mineral density.
Published: 2018

11. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy

Author: Belmonti, Simone, Lombardi, Francesca, Quiros-Roldan, Eugenia, Latini, Alessandra, Castagna, Antonella, Borghetti, Alberto, Baldin, Gianmaria, Ciccullo, Arturo, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Giacometti, Andrea, Di Pietro, Massimo, Mughini, Maria Teresa, Grima, Pierfrancesco, Viscoli, Claudio, Manconi, Paolo Emilio, Puoti, Massimo, Galli, Massimo, Viale, Pierluigi, Gori, Andrea, Rizzardini, Giuliano, Mineo, Maurizio, Antinori, Andrea, Petrosillo, Nicola, Vullo, Vincenzo, Stella Mura, Maria, Caramello, Pietro, Scotton, Pier Giorgio, Concia, Ercole, Lazzarin, Adriano, Francisci, Daniela, Sacchini, Daria, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Belmonti, Simone, Lombardi, Francesca, Quiros-Roldan, Eugenia, Latini, Alessandra, Castagna, Antonella, Borghetti, Alberto, Baldin, Gianmaria, Ciccullo, Arturo, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Giacometti, Andrea, Di Pietro, Massimo, Mughini, Maria Teresa, Grima, Pierfrancesco, Viscoli, Claudio, Manconi, Paolo Emilio, Puoti, Massimo, Galli, Massimo, Viale, Pierluigi, Gori, Andrea, Rizzardini, Giuliano, Mineo, Maurizio, Antinori, Andrea, Petrosillo, Nicola, Vullo, Vincenzo, Stella Mura, Maria, Caramello, Pietro, Scotton, Pier Giorgio, Concia, Ercole, Lazzarin, Adriano, Francisci, Daniela, Sacchini, Daria, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: Background Biomarkers of systemic inflammation predict non-AIDS events and overall mortality in virologically suppressed HIV-1-infected patients. Objectives To determine whether switching to a dual antiretroviral maintenance therapy was associated with modification of biomarkers of systemic inflammation as compared with continuation of successful standard triple therapy. Methods In this substudy of the randomized ATLAS-M trial, we compared in virologically suppressed patients the impact at 1 year of simplification to a dual therapy with atazanavir/ritonavir plus lamivudine versus maintaining atazanavir/ritonavir plus two NRTI triple therapy on markers of systemic inflammation. Plasma levels of interleukin-6, C-reactive protein (CRP), soluble CD14 (sCD14) and D-dimer were quantified by ELISA at baseline and at 48 weeks. Results A subset of 139 of 266 randomized patients with available samples was analysed: 69 in the triple therapy arm and 70 in the dual therapy arm. The baseline biomarker levels were comparable between randomization arms. No significant differences in changes from baseline to week 48 were observed between arms (dual therapy versus triple therapy): IL-6, −0.030 versus −0.016 log10 pg/L; CRP, +0.022 versus +0.027 log10 pg/mL; sCD14, −0.016 versus +0.019 log10 pg/mL; and D-dimer, −0.031 versus +0.004 log10 pg/mL. A history of cancer was associated with higher baseline levels of IL-6 (P = 0.002) and CRP (P = 0.049). No relationship was observed between baseline biomarker level and persistent residual viraemia, HIV-1 DNA load, plasma lipids and other potential explanatory variables. Conclusions Simplification with atazanavir/ritonavir plus lamivudine does not affect plasma markers of systemic inflammation in virologically suppressed patients. The association between these findings and clinical outcomes requires further evaluation
Published: 2018

12. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients

Author: Borghetti, Alberto, Baldin, Gianmaria, Capetti, Amedeo, Sterrantino, Gaetana, Rusconi, Stefano, Latini, Alessandra, Giacometti, Andrea, Madeddu, Giordano, Picarelli, Chiara, De Marco, Ramona, Cossu, Maria V., Lagi, Filippo, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Borghetti, Alberto, Baldin, Gianmaria, Capetti, Amedeo, Sterrantino, Gaetana, Rusconi, Stefano, Latini, Alessandra, Giacometti, Andrea, Madeddu, Giordano, Picarelli, Chiara, De Marco, Ramona, Cossu, Maria V., Lagi, Filippo, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: Not Available N/A
Published: 2017

13. Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

Author: Rossetti, Barbara, Gagliardini, Roberta, Meini, Genny, Sterrantino, Gaetana, Colangeli, Vincenzo, Re, Maria Carla, Latini, Alessandra, Colafigli, Manuela, Vignale, Francesca, Rusconi, Stefano, Micheli, Valeria, Biagio, Antonio Di, Orofino, Giancarlo, Ghisetti, Valeria, Fantauzzi, Alessandra, Vullo, Vincenzo, Grima, Pierfrancesco, Francisci, Daniela, Mastroianni, Claudio, Antinori, Andrea, Trezzi, Michele, Lisi, Lucia, Navarra, Pierluigi, Canovari, Benedetta, D’Arminio Monforte, Antonella, Lamonica, Silvia, D'Avino, Alessandro, Zazzi, Maurizio, Di Giambenedetto, Simona, De Luca, Andrea, Lisi, Lucia (ORCID:0000-0003-1397-2426), Navarra, Pierluigi (ORCID:0000-0002-4424-650X), D’Avino, Alessandro, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), De Luca, Andrea (ORCID:0000-0002-8311-6935), Rossetti, Barbara, Gagliardini, Roberta, Meini, Genny, Sterrantino, Gaetana, Colangeli, Vincenzo, Re, Maria Carla, Latini, Alessandra, Colafigli, Manuela, Vignale, Francesca, Rusconi, Stefano, Micheli, Valeria, Biagio, Antonio Di, Orofino, Giancarlo, Ghisetti, Valeria, Fantauzzi, Alessandra, Vullo, Vincenzo, Grima, Pierfrancesco, Francisci, Daniela, Mastroianni, Claudio, Antinori, Andrea, Trezzi, Michele, Lisi, Lucia, Navarra, Pierluigi, Canovari, Benedetta, D’Arminio Monforte, Antonella, Lamonica, Silvia, D'Avino, Alessandro, Zazzi, Maurizio, Di Giambenedetto, Simona, De Luca, Andrea, Lisi, Lucia (ORCID:0000-0003-1397-2426), Navarra, Pierluigi (ORCID:0000-0002-4424-650X), D’Avino, Alessandro, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Objectives: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. Methods: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART (continuation arm). Results: In June 2015, 115 patients were evaluable for the primary outcome (56 study, 59 continuation arm). The study was discontinued due to excess of VF in the study arm (7 cases, 12.5%, vs 0 in the continuation arm, p = 0.005). The proportion free of treatment failure was 73.2% in the study and 59.3% in the continuation arm. Two participants in the study and 10 in the continuation arm discontinued therapy due to adverse events (p = 0.030). At VF, no emergent drug resistance was detected. Co-receptor tropism switched to non-R5 in one patient. Patients with VF reported lower adherence and had lower plasma drug levels. Femoral bone mineral density was significantly improved in the study arm. Conclusion: Switching to maraviroc with darunavir/ritonavir qd in virologically suppressed patients was associated with improved tolerability but was virologically inferior to 3-drug therapy.
Published: 2017

14. 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir

Author: Gagliardini, Roberta, Bandera, Alessandra, Zaccarelli, Mauro, Sterrantino, Gaetana, Latini, Alessandra, D'Avino, Alessandro, Lapadula, Giuseppe, Antinori, Andrea, Cauda, Roberto, De Luca, Andrea, Gori, Andrea, Di Giambenedetto, Simona, Fabbiani, Massimiliano, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Gagliardini, Roberta, Bandera, Alessandra, Zaccarelli, Mauro, Sterrantino, Gaetana, Latini, Alessandra, D'Avino, Alessandro, Lapadula, Giuseppe, Antinori, Andrea, Cauda, Roberto, De Luca, Andrea, Gori, Andrea, Di Giambenedetto, Simona, Fabbiani, Massimiliano, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: BACKGROUND: Few data are available about efficacy and durability of simplification from multi-tablet antiretroviral regimens to co-formulated efavirenz (EFV)/emtricitabine (FTC)/tenofovir (TDF) versus rilpivirine (RPV)/FTC/TDF in virologically suppressed HIV-1-infected patients. METHODS: We retrospectively analysed HIV-infected patients with HIV RNA <50 copies/ml switching to co-formulated EFV/FTC/TDF or RPV/FTC/TDF at five Italian centres. Patients were followed from time of switch until regimen discontinuation or a maximum of 3-years follow-up. Time to treatment discontinuation (TD) and virological failure (VF; defined as two consecutive HIV RNA >50 copies/ml or a single determination >1,000 copies/ml) and their predictors were investigated. RESULTS: 1,560 patients were reviewed of which 1,097 (70%) switched to EFV/FTC/TDF and 463 (30%) to RPV/FTC/TDF. During follow-up, VF and TD occurred in 44 (4%) and 242 (22%) patients in EFV/FTC/TDF and in 29 (6%) and 50 (11%) patients in RPV/FTC/TDF, respectively. The 3-year estimated probability of remaining free from VF was 96.2% with EFV/FTC/TDF versus 92.7% with RPV/FTC/TDF (P=0.003). At multivariate analysis, regimen type (EFV/FTC/TDF versus RPV/FTC/TDF aHR 0.24; P=0.004) and time of virological suppression (aHR 0.85; P=0.048) were the only independent predictors of VF. The estimated 3-year probability of remaining free from TD was 77.4% with EFV/FTC/TDF versus 88.4% with RPV/FTC/TDF (P=0.001). Predictors of TD were female sex, switching from PI-based regimens, older age, shorter time of virological suppression and regimen type (EFV/FTC/TDF versus RPV/FTC/TDF aHR 2.48; P<0.001). RPV/FTC/TDF showed a safer lipid profile and a greater increase in creatinine. CONCLUSIONS: Both regimens showed good safety and efficacy in this real-life setting, although switch to RPV/FTC/TDF seemed better tolerated while EFV/FTC/TDF was associated with a lower probability of VF.
Published: 2017

15. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

Author: Petta, Salvatore, Marzioni, Marco, Russo, Pierluigi, Aghemo, Alessio, Alberti, Alfredo, Ascione, Antonio, Antinori, Andrea, Bruno, Raffaele, Bruno, Savino, Chirianni, Antonio, Gaeta, Giovanni Battista, Giannini, Edoardo G, Merli, Manuela, Messina, Vincenzo, Montilla, Simona, Perno, Carlo Federico, Puoti, Massimo, Raimondo, Giovanni, Rendina, Maria, Silberstein, Francesca Ceccherini, Villa, Erica, Zignego, Anna Linda, Pani, Luca, Craxã¬, Antonio, Tabone, Marco, Andreoni, Massimo, Teti, Elisabetta, Angelico, Mario, Persico, Marcello, Masarone, Mario, Chiodera, Aledssandro, Solinas, Attilio, delle Monache, Marco, Cecere, Roberto, Maria Schimizzi, Anna, Piovesan, Sara, Campagnolo, Davide, Chiara Piras, Maria, Zolfino, Teresa, Paolo Russo, Francesca, Morelli, Olivia, Sangiovanni, Vincenzo, Onofrio, Mirella, Iodice, Valentina, Izzi, Antonio, Pirisi, Massimo, Danieli, Elena, Vinci, Maria Rosaria, Rizzardini, Giuliano, Fagiuoli, Stefano, Pasulo, Luisa, D'Arminio Monforte, Antonella, Zuin, Massimo, Giorgini, Alessia, Simeone, Filomena, Piali, Guido, Lo Guercio, Carmela, Federico, Alessandro, Brancaccio, Giuseppina, Marrone, Aldo, Abbati, Giuseppe, Boarini, Chiara, Borghi, Vanni, Bernabucci, Veronica, Corti, Giampaolo, Monti, Monica, Rizzetto, Mario, Martini, Silvia, Andreone, Pietro, Gianstefani, Alice, Lenzi, Marco, Verucchi, Gabriella, Toniutto, Pierluigi, Borgia, Guglielmo, Caporaso, Nicola, Morisco, Filomena, Nardone, Gaetano, Angrisani, Debora, Giacometti, Andrea, Benedetti, Antonio, Tarantino, Giuseppe, Marsetti, Fabio, Tavio, Marcello, Novara, Sergio, Antonia Santantonio, Teresa, Serviddio, Gaetano, Brunetto, Maurizia, Coco, Barbara, Angarano, Gioacchino, Milella, Michele, Barone, Michele, Di Leo, Alfredo, Ettore Sansonno, Domenico, Cacciola, Irene, Boffa, Nicola, Saracco, Giorgio, Di Biagio, Antonio, Picciotto, Antonino, De Luca, Andrea, Calvaruso, Vincenza, Corradori, Silvia, Ferrari, Carlo, Orlandini, Alessandra, Maida, Ivana, Torti, Carlo, Chessa, Luchino, Felder, Martina, Vespasiani Gentilucci, Umberto, Angeli, Paolo, Romano, Antonietta, Rapaccini, Gian Ludovico, Miele, Luca, Cima, Serena, Russo, Maria Luisa, Cozzolongo, Raffaele, Onnelli, Giovanna, D'Offizi, Giampiero, Lionetti, Raffaella, Montalbano, Marzia, Guerra, Michele, Di Perri, Giovanni, Boglione, Lucio, Capra, Franco, Carolo, Giada, Ieluzzi, Donatella, Antonini, Cinzia, Termite, Antonio, Madonia, Salvatore, Tarquini, Pierluigi, Parruti, Giustino, Vecchiet, Giacomo, Falasca, Katia, Menzaghi, Barbara, Quirino, Tiziana, Dentone, Chiara, Maria Piscaglia, Anna, Rossi, Cristina, Giordani, Maria, Fontanella, Luca, Cassola, Giovanni, Russello, Maurizio, Cristaudo, Antonio, Giacomet, Vania, Colombo, Massimo, Donato, Francesca, Durante, Emanuele, Cosco, Lucio, Marignani, Massimo, Quartini, Mariano, Memoli, Massimo, Ganga, Roberto, Ponti, Laura, Soria, Alessandro, Grazia Rumi, Maria, Gulminetti, Roberto, Maserati, Renato, Mondelli, Mario, Lazzarin, Adriano, Rita Parisi, Maria, Canovari, Benedetta, Avancini, Ivo, Pravadelli, Cecilia, Blanc, Pier, Pasquazzi, Caterina, Maria Mastroianni, Claudio, Lichtner, Myriam, Distefano, Marco, Magnani, Silvia, Paganin, Simona, Erne, Elke, Gatti, Pietro, Tundi, Paolo, Calabrese, Paolo, Gasbarrini, Antonio, Grieco, Antonio, Coppola, Nicola, Del Poggio, Paolo, Levrero, Massimo, Talliani, Gloria, Vullo, Vincenzo, Cauda, Roberto, La Monica, Silvia, Potenza, Domenico, Rizzo, Salvatore, Castelli, Francesco, Marie Pigozzi, Grazielle, Ciancio, Alessia, Romagnoli, Dante, Barchetti, Federica, Ivanovic, Jelena, Longo, Olimpia, Petraglia, Sandra, Paola Trotta, Maria, Vinci, Maria, de Luca, Andrea (ORCID:0000-0002-8311-6935), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Miele, Luca (ORCID:0000-0003-3464-0068), Luisa Russo, Maria, Gasbarrini,Antonio (ORCID:0000-0002-7278-4823), Grieco,Antonio (ORCID:0000-0002-0544-8993), Cauda,Roberto (ORCID:0000-0002-1498-4229), Petta, Salvatore, Marzioni, Marco, Russo, Pierluigi, Aghemo, Alessio, Alberti, Alfredo, Ascione, Antonio, Antinori, Andrea, Bruno, Raffaele, Bruno, Savino, Chirianni, Antonio, Gaeta, Giovanni Battista, Giannini, Edoardo G, Merli, Manuela, Messina, Vincenzo, Montilla, Simona, Perno, Carlo Federico, Puoti, Massimo, Raimondo, Giovanni, Rendina, Maria, Silberstein, Francesca Ceccherini, Villa, Erica, Zignego, Anna Linda, Pani, Luca, Craxã¬, Antonio, Tabone, Marco, Andreoni, Massimo, Teti, Elisabetta, Angelico, Mario, Persico, Marcello, Masarone, Mario, Chiodera, Aledssandro, Solinas, Attilio, delle Monache, Marco, Cecere, Roberto, Maria Schimizzi, Anna, Piovesan, Sara, Campagnolo, Davide, Chiara Piras, Maria, Zolfino, Teresa, Paolo Russo, Francesca, Morelli, Olivia, Sangiovanni, Vincenzo, Onofrio, Mirella, Iodice, Valentina, Izzi, Antonio, Pirisi, Massimo, Danieli, Elena, Vinci, Maria Rosaria, Rizzardini, Giuliano, Fagiuoli, Stefano, Pasulo, Luisa, D'Arminio Monforte, Antonella, Zuin, Massimo, Giorgini, Alessia, Simeone, Filomena, Piali, Guido, Lo Guercio, Carmela, Federico, Alessandro, Brancaccio, Giuseppina, Marrone, Aldo, Abbati, Giuseppe, Boarini, Chiara, Borghi, Vanni, Bernabucci, Veronica, Corti, Giampaolo, Monti, Monica, Rizzetto, Mario, Martini, Silvia, Andreone, Pietro, Gianstefani, Alice, Lenzi, Marco, Verucchi, Gabriella, Toniutto, Pierluigi, Borgia, Guglielmo, Caporaso, Nicola, Morisco, Filomena, Nardone, Gaetano, Angrisani, Debora, Giacometti, Andrea, Benedetti, Antonio, Tarantino, Giuseppe, Marsetti, Fabio, Tavio, Marcello, Novara, Sergio, Antonia Santantonio, Teresa, Serviddio, Gaetano, Brunetto, Maurizia, Coco, Barbara, Angarano, Gioacchino, Milella, Michele, Barone, Michele, Di Leo, Alfredo, Ettore Sansonno, Domenico, Cacciola, Irene, Boffa, Nicola, Saracco, Giorgio, Di Biagio, Antonio, Picciotto, Antonino, De Luca, Andrea, Calvaruso, Vincenza, Corradori, Silvia, Ferrari, Carlo, Orlandini, Alessandra, Maida, Ivana, Torti, Carlo, Chessa, Luchino, Felder, Martina, Vespasiani Gentilucci, Umberto, Angeli, Paolo, Romano, Antonietta, Rapaccini, Gian Ludovico, Miele, Luca, Cima, Serena, Russo, Maria Luisa, Cozzolongo, Raffaele, Onnelli, Giovanna, D'Offizi, Giampiero, Lionetti, Raffaella, Montalbano, Marzia, Guerra, Michele, Di Perri, Giovanni, Boglione, Lucio, Capra, Franco, Carolo, Giada, Ieluzzi, Donatella, Antonini, Cinzia, Termite, Antonio, Madonia, Salvatore, Tarquini, Pierluigi, Parruti, Giustino, Vecchiet, Giacomo, Falasca, Katia, Menzaghi, Barbara, Quirino, Tiziana, Dentone, Chiara, Maria Piscaglia, Anna, Rossi, Cristina, Giordani, Maria, Fontanella, Luca, Cassola, Giovanni, Russello, Maurizio, Cristaudo, Antonio, Giacomet, Vania, Colombo, Massimo, Donato, Francesca, Durante, Emanuele, Cosco, Lucio, Marignani, Massimo, Quartini, Mariano, Memoli, Massimo, Ganga, Roberto, Ponti, Laura, Soria, Alessandro, Grazia Rumi, Maria, Gulminetti, Roberto, Maserati, Renato, Mondelli, Mario, Lazzarin, Adriano, Rita Parisi, Maria, Canovari, Benedetta, Avancini, Ivo, Pravadelli, Cecilia, Blanc, Pier, Pasquazzi, Caterina, Maria Mastroianni, Claudio, Lichtner, Myriam, Distefano, Marco, Magnani, Silvia, Paganin, Simona, Erne, Elke, Gatti, Pietro, Tundi, Paolo, Calabrese, Paolo, Gasbarrini, Antonio, Grieco, Antonio, Coppola, Nicola, Del Poggio, Paolo, Levrero, Massimo, Talliani, Gloria, Vullo, Vincenzo, Cauda, Roberto, La Monica, Silvia, Potenza, Domenico, Rizzo, Salvatore, Castelli, Francesco, Marie Pigozzi, Grazielle, Ciancio, Alessia, Romagnoli, Dante, Barchetti, Federica, Ivanovic, Jelena, Longo, Olimpia, Petraglia, Sandra, Paola Trotta, Maria, Vinci, Maria, de Luca, Andrea (ORCID:0000-0002-8311-6935), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Miele, Luca (ORCID:0000-0003-3464-0068), Luisa Russo, Maria, Gasbarrini,Antonio (ORCID:0000-0002-7278-4823), Grieco,Antonio (ORCID:0000-0002-0544-8993), and Cauda,Roberto (ORCID:0000-0002-1498-4229)
Abstract: Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with HCV genotype 1b infection) or 24 weeks (patients with HCV genotype 1a infection). Patients with HCV genotype 4 infection were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once per day for 24 weeks. All patients were given weight-based ribavirin. The primary efficacy endpoint was sustained virological response at week 12 after the end of treatment (SVR12), analysed by intention-to-treat. Univariate and multivariate logistic regression analyses were used to identify baseline characteristics associated with SVR12. Adverse events were recorded throughout the study. Findings 728 (96%) of 762 patients with cirrhosis who were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12. Logistic regression analyses identified that bilirubin concentrations of less than 2 mg/dL were associated with SVR12 (odds ratio [OR] 4Â·76 [95% CI 1Â·83â12Â·3]; p=0Â·001). 166 (23%) of 734 patients included in safety analyses had an adverse event. 25 (3%) patients discontinued treatment because of adverse events. Asthenia was the most commonly reported adverse event, occurring i
Published: 2017

16. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL

Author: Madeddu, Giordano, Rusconi, Stefano, Cozzi Lepri, Alessandro, Di Giambenedetto, Simona, Bonora, Stefano, Carbone, Alessia, De Luca, Andrea, Gianotti, Nicola, Di Biagio, Antonio, Antinori, Andrea, D’Arminio Monforte, A., Andreoni, M., Angarano, G., Antinori, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., von Schloesser, F., Viale, P., Castagna, A., Ceccherini Silberstein, F., Cozzi Lepri, A., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Borderi, M., Calcagno, A., Calza, L., Capobianchi, M. R., Cingolani, A., Cinque, P., Lichtner, A., Madeddu, G., Maggiolo, F., Marchetti, G., Marcotullio, S., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M. M., Saracino, A., Zaccarelli, M., Fanti, Iuri, Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Tavelli, A., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, A., Costantini, A., Valeriani, C., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Vichi, F., Cassola, G., Viscoli, C., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Gori, A., Guaraldi, G., Lapadula, G., Abrescia, N., Chirianni, A., Borgia, G., Di Martino, F., Maddaloni, L., Gentile, I., Orlando, R., Cascio, A., Colomba, C., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Vullo, V., Cristaudo, A., Baldin, Gianmaria, Cicalini, S., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Savinelli, S., Latini, A., Iaiani, G., Fontanelli Sulekova, L., Cecchetto, M., Viviani, F., Mura, M. S., de Luca, A., Rossetti, Barbara, Caramello, P., Orofino, G. C., Bonora, S., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), De Luca, Andrea (ORCID:0000-0002-8311-6935), Cauda, Roberto (ORCID:0000-0002-1498-4229), Madeddu, Giordano, Rusconi, Stefano, Cozzi Lepri, Alessandro, Di Giambenedetto, Simona, Bonora, Stefano, Carbone, Alessia, De Luca, Andrea, Gianotti, Nicola, Di Biagio, Antonio, Antinori, Andrea, D’Arminio Monforte, A., Andreoni, M., Angarano, G., Antinori, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., von Schloesser, F., Viale, P., Castagna, A., Ceccherini Silberstein, F., Cozzi Lepri, A., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Borderi, M., Calcagno, A., Calza, L., Capobianchi, M. R., Cingolani, A., Cinque, P., Lichtner, A., Madeddu, G., Maggiolo, F., Marchetti, G., Marcotullio, S., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M. M., Saracino, A., Zaccarelli, M., Fanti, Iuri, Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Tavelli, A., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, A., Costantini, A., Valeriani, C., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Vichi, F., Cassola, G., Viscoli, C., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Gori, A., Guaraldi, G., Lapadula, G., Abrescia, N., Chirianni, A., Borgia, G., Di Martino, F., Maddaloni, L., Gentile, I., Orlando, R., Cascio, A., Colomba, C., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Vullo, V., Cristaudo, A., Baldin, Gianmaria, Cicalini, S., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Savinelli, S., Latini, A., Iaiani, G., Fontanelli Sulekova, L., Cecchetto, M., Viviani, F., Mura, M. S., de Luca, A., Rossetti, Barbara, Caramello, P., Orofino, G. C., Bonora, S., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Cauda, Roberto (ORCID:0000-0002-1498-4229)
Abstract: Background: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. Objectives: We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting. Study design: Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Different definitions of virological failure (VF) and treatment failure (TF) were employed. Kaplan–Meier curves and Cox regression models were performed to estimate time to event probability. Results: We included 72 HIV-infected patients, 22 (31%) of these were female, 31 (43%) men who have sex with men (MSM) amd 15 (21%) had hepatitis co-infections. Median age was 44 (IQR: 35-50) years amd CD4 count was 389 (IQR 283-606) cells/mmc. Median follow-up time for TF was 24 (IQR 9–31) months. Twenty-five discontinuations occurred (60% simplifications); only 2 (8%) were toxicity-driven (lipid elevations). The probability of VF (confirmed VL >50 copies/mL) was estimated at 7% [95% confidence interval (CI) 1–13%] by 12 and 9% (95% CI 2–16%) by 24 months. When considering TF, we found a probability of stop/intensification/single VL > 200 copies/mL of 13% (95% CI 1–17%) and 22% (95% CI 11–33%) by 12 and 24 months. Female gender (adjusted relative hazard, ARH = 0.10; 95% CI 0.01–0.74; p = 0.024) and older age (AHR = 0.50 per 10 years older; 95% CI 0.25–0.99; p = 0.045) were associated with a lower risk of TF. A previous PI failure was strongly associated with TF (AHR = 52.6, 95% CI 3.6–779; p = 0.004). Conclusions: DRV/r + RAL is a valuable NRTI-sparing option, especially in female and older patients, with a relat
Published: 2017

17. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort

Author: d'Arminio Monforte, Antonella, Cozzi Lepri, Alessandro, Ceccherini Silberstein, Francesca, De Luca, Andrea, Lo Caputo, Sergio, Castagna, Antonella, Mussini, Cristina, Cingolani, Antonella, Tavelli, Alessandro, Shanyinde, Milensu, Gori, Andrea, Girardi, Enrico, Andreoni, Massimo, Antinori, Andrea, Puoti, Massimo, De Luca, Andrea (ORCID:0000-0002-8311-6935), Cingolani, Antonella (ORCID:0000-0002-3793-2755), d'Arminio Monforte, Antonella, Cozzi Lepri, Alessandro, Ceccherini Silberstein, Francesca, De Luca, Andrea, Lo Caputo, Sergio, Castagna, Antonella, Mussini, Cristina, Cingolani, Antonella, Tavelli, Alessandro, Shanyinde, Milensu, Gori, Andrea, Girardi, Enrico, Andreoni, Massimo, Antinori, Andrea, Puoti, Massimo, De Luca, Andrea (ORCID:0000-0002-8311-6935), and Cingolani, Antonella (ORCID:0000-0002-3793-2755)
Abstract: not available
Published: 2017

18. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

Author: Lombardi, Francesca, Belmonti, Simone, Quiros Roldan, Eugenia, Latini, Alessandra, Castagna, Antonella, D'Ettorre, Gabriella, Gagliardini, Roberta, Fabbiani, Massimiliano, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Lombardi, Francesca, Belmonti, Simone, Quiros Roldan, Eugenia, Latini, Alessandra, Castagna, Antonella, D'Ettorre, Gabriella, Gagliardini, Roberta, Fabbiani, Massimiliano, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: OBJECTIVES: The AtLaS-M randomized trial showed that in patients with HIV-1 RNA <50 copies/mL on atazanavir/ritonavir + two NRTIs, switching to a dual therapy with atazanavir/ritonavir+lamivudine had superior efficacy as compared with continuing the previous triple therapy. This substudy was designed to evaluate at 48 weeks the impact of the dual therapy versus the three-drug atazanavir/ritonavir-based therapy on the HIV-1 cellular reservoir as reflected by the quantification of blood-associated HIV-1 DNA levels. METHODS: In a representative subset of 201 of 266 randomized patients (104 in the dual-therapy arm and 97 in the triple-therapy arm) total HIV-1 DNA levels in whole blood at baseline and after 48 weeks and factors associated with the HIV-1 DNA levels were evaluated. RESULTS: The mean baseline HIV-1 DNA levels (2.47 log 10 copies/10 6 leucocytes) were comparable between arms. A significant mean decrease between baseline and week 48 was observed: -0.069 log 10 copies/10 6 leucocytes in the dual-therapy arm ( P = 0.046) and -0.078 in the triple-therapy arm ( P = 0.011); the mean difference between arms was -0.009 ( P = 0.842). Nadir CD4 count was inversely correlated with baseline HIV-1 DNA ( P = 0.009); longer duration of ART and lower nadir CD4 correlated with a less prominent HIV-1 DNA decrease (both P < 0.005). Higher baseline HIV-1 DNA was associated with residual viraemia at week 48 ( P = 0.031). CONCLUSIONS: When compared with continuing three-drug therapy, atazanavir/ritonavir+lamivudine dual therapy resulted in a similar decline in HIV-1 DNA levels in patients with sustained virological suppression. These data support the safety of this simplified treatment strategy in terms of its effect on the cellular HIV-1 reservoir
Published: 2017

19. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients

Author: Borghetti, Alberto, Baldin, Gianmaria, Capetti, Amedeo, Sterrantino, Gaetana, Rusconi, Stefano, Latini, Alessandra, Giacometti, Andrea, Madeddu, Giordano, Picarelli, Chiara, De Marco, Ramona, Cossu, Maria V., Lagi, Filippo, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Borghetti, Alberto, Baldin, Gianmaria, Capetti, Amedeo, Sterrantino, Gaetana, Rusconi, Stefano, Latini, Alessandra, Giacometti, Andrea, Madeddu, Giordano, Picarelli, Chiara, De Marco, Ramona, Cossu, Maria V., Lagi, Filippo, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: Not Available
Published: 2017

20. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)

Author: Di Giambenedetto, Simona, Fabbiani, Massimiliano, Quiros Roldan, Eugenia, Latini, Alessandra, D'Ettorre, Gabriella, Antinori, Andrea, Castagna, Antonella, Orofino, Giancarlo, Francisci, Daniela, Chinello, Pierangelo, Madeddu, Giordano, Grima, Pierfrancesco, Rusconi, Stefano, Di Pietro, Massimo, Mondi, Annalisa, Ciccarelli, Nicoletta, Borghetti, Alberto, Focà, Emanuele, Colafigli, Manuela, De Luca, Andrea, Cauda, Roberto, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), De Luca, Andrea (ORCID:0000-0002-8311-6935), Cauda, Roberto (ORCID:0000-0002-1498-4229), Di Giambenedetto, Simona, Fabbiani, Massimiliano, Quiros Roldan, Eugenia, Latini, Alessandra, D'Ettorre, Gabriella, Antinori, Andrea, Castagna, Antonella, Orofino, Giancarlo, Francisci, Daniela, Chinello, Pierangelo, Madeddu, Giordano, Grima, Pierfrancesco, Rusconi, Stefano, Di Pietro, Massimo, Mondi, Annalisa, Ciccarelli, Nicoletta, Borghetti, Alberto, Focà, Emanuele, Colafigli, Manuela, De Luca, Andrea, Cauda, Roberto, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Cauda, Roberto (ORCID:0000-0002-1498-4229)
Abstract: not available
Published: 2017

21. Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study

Author: Wang, Qing, De Luca, Andrea, Smith, Colette, Zangerle, Robert, Sambatakou, Helen, Bonnet, Fabrice, Smit, Colette, Schommers, Philipp, Thornton, Alicia, Berenguer, Juan, Peters, Lar, Spagnuolo, Vincenzo, Ammassari, Adriana, Antinori, Andrea, Quiros Roldan, Eugenia, Mussini, Cristina, Miro, Jose M, Konopnicki, Deborah, Fehr, Jan, Campbell, Maria A, Termote, Monique, Bucher, Heiner C., De Luca, Andrea (ORCID:0000-0002-8311-6935), Wang, Qing, De Luca, Andrea, Smith, Colette, Zangerle, Robert, Sambatakou, Helen, Bonnet, Fabrice, Smit, Colette, Schommers, Philipp, Thornton, Alicia, Berenguer, Juan, Peters, Lar, Spagnuolo, Vincenzo, Ammassari, Adriana, Antinori, Andrea, Quiros Roldan, Eugenia, Mussini, Cristina, Miro, Jose M, Konopnicki, Deborah, Fehr, Jan, Campbell, Maria A, Termote, Monique, Bucher, Heiner C., and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: not available
Published: 2017

22. Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients

Author: Fabbiani, Massimiliano, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Poli, Andrea, Borghetti, Alberto, Castagna, Antonella, Mondi, Annalisa, Galizzi, Nadia, Maillard, Myriam, Gori, Andrea, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Gianotti, Nicola, Fabbiani, Massimiliano, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Poli, Andrea, Borghetti, Alberto, Castagna, Antonella, Mondi, Annalisa, Galizzi, Nadia, Maillard, Myriam, Gori, Andrea, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Gianotti, Nicola
Abstract: not available
Published: 2016

23. HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug Users

Author: Lai, A, Bozzi, G, Franzetti, M, Binda, F, Simonetti, Fr, De Luca, Andrea, Micheli, V, Meraviglia, P, Bagnarelli, P, Di Biagio, A, Monno, L, Saladini, F, Zazzi, M, Zehender, G, Ciccozzi, M, Balotta, C., De Luca, Andrea (ORCID:0000-0002-8311-6935), Lai, A, Bozzi, G, Franzetti, M, Binda, F, Simonetti, Fr, De Luca, Andrea, Micheli, V, Meraviglia, P, Bagnarelli, P, Di Biagio, A, Monno, L, Saladini, F, Zazzi, M, Zehender, G, Ciccozzi, M, Balotta, C., and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Subtype A accounts for only 12% of HIV-1 infections worldwide but predominates in Russia and Former Soviet Union countries of Eastern Europe. After an early propagation via heterosexual contacts, this variant spread explosively among intravenous drug users. A distinct A1 variant predominates in Greece and Albania, which penetrated directly from Africa. Clade A1 accounts for 12.5% of non-B subtypes in Italy, being the most frequent after F1 subtype.
Published: 2016

24. Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy

Author: Di Biagio, Antonio, Cozzi Lepri, Alessandro, Prinapori, Roberta, Angarano, Gioacchino, Gori, Andrea, Quirino, Tiziana, De Luca, Andrea, Costantini, Andrea, Mussini, Cristina, Rizzardini, Giuliano, Castagna, Antonella, Antinori, Andrea, Monforte, Antonella D'arminio, Moroni, M., Andreoni, M., Angarano, G., Antinori, A., D'Arminio Monforte, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., Von Schloesser, F., Viale, P., Castagna, A., Ceccherini Silberstein, F., Cozzi Lepri, A., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Bonora, S., Borderi, M., Calcagno, A., Calza, L., Capobianchi, M. R., Cingolani, Antonella, Cinque, P., De Luca, A., Di Biagio, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Maggiolo, F., Marchetti, G., Marcotullio, S., Monno, L., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M., Saracino, A., Zaccarelli, M., Fanti, Iuri, Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Tavelli, A., Giacometti, A., Costantini, A., Mazzoccato, S., Santoro, C., Suardi, C., Vanino, E., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Cassola, G., Viscoli, C., Alessandrini, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Guida, M. G., Gargiulo, M., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Cauda, R., Vullo, V., Cingolani, A., D'Avino, Alessandro, Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Tebano, G., Viviani, F., Sasset, L., Mura, M. S., Rossetti, Barbara, Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., De Luca, Andrea (ORCID:0000-0002-8311-6935), Cauda, Roberto (ORCID:0000-0002-1498-4229), Cingolani, Antonella (ORCID:0000-0002-3793-2755), Di Biagio, Antonio, Cozzi Lepri, Alessandro, Prinapori, Roberta, Angarano, Gioacchino, Gori, Andrea, Quirino, Tiziana, De Luca, Andrea, Costantini, Andrea, Mussini, Cristina, Rizzardini, Giuliano, Castagna, Antonella, Antinori, Andrea, Monforte, Antonella D'arminio, Moroni, M., Andreoni, M., Angarano, G., Antinori, A., D'Arminio Monforte, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., Von Schloesser, F., Viale, P., Castagna, A., Ceccherini Silberstein, F., Cozzi Lepri, A., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Bonora, S., Borderi, M., Calcagno, A., Calza, L., Capobianchi, M. R., Cingolani, Antonella, Cinque, P., De Luca, A., Di Biagio, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Maggiolo, F., Marchetti, G., Marcotullio, S., Monno, L., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M., Saracino, A., Zaccarelli, M., Fanti, Iuri, Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Tavelli, A., Giacometti, A., Costantini, A., Mazzoccato, S., Santoro, C., Suardi, C., Vanino, E., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Cassola, G., Viscoli, C., Alessandrini, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Guida, M. G., Gargiulo, M., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Cauda, R., Vullo, V., Cingolani, A., D'Avino, Alessandro, Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Tebano, G., Viviani, F., Sasset, L., Mura, M. S., Rossetti, Barbara, Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., De Luca, Andrea (ORCID:0000-0002-8311-6935), Cauda, Roberto (ORCID:0000-0002-1498-4229), and Cingolani, Antonella (ORCID:0000-0002-3793-2755)
Abstract: Background: Study aim was to estimate the rate and identify predictors of discontinuation of first combination antiretroviral therapy (cART) in recent years. Methods: Patients who initiated first cART between January 2008 and October 2014 were included. Discontinuation was defined as stop of at least 1 drug of the regimen, regardless of the reason. All causes of discontinuation were evaluated and 3 main endpoints were considered: toxicity, intolerance, and simplification. Predictors of discontinuation were examined separately for all 3 endpoints. Kaplan-Meier analysis was used for the outcome discontinuation of ≥1 drug regardless of the reason. Cox regression analysis was used to identify factors associated with treatment discontinuation because of the 3 reasons considered. Results: A total of 4052 patients were included. Main reason for stopping at least 1 drug were simplification (29%), intolerance (21%), toxicity (19%), other causes (18%), failure (8%), planned discontinuation (4%), and nonadherence (2%). In a multivariable Cox model, predictors of discontinuation for simplification were heterosexual transmission (P = 0.007), being immigrant (P = 0.017), higher nadir lymphocyte T CD4+cell (P = 0.011), and higher lymphocyte T CD8+cell count (P = 0.025); for discontinuation due to intolerance: the use of statins (P = 0.029), higher blood glucose levels (P = 0.050). About toxicity: higher blood glucose levels (P = 0.010) and the use of zidovudine/lamivudine as backbone (P = 0.044). Conclusions: In the late cART era, the main reason for stopping the initial regimen is simplification. This scenario reflects the changes in recommendations aimed to enhance adherence and quality of life, and minimize drug toxicity.
Published: 2016

25. Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression

Author: Castagna, Antonella, Monno, Laura, Carta, Stefania, Galli, Laura, Carrara, Stefania, Fedele, Valentina, Punzi, Grazia, Fanti, Iuri, Caramello, Pietro, Lepri, Alessandro Cozzi, De Luca, Andrea, Ceccherini Silberstein, Francesca, D'Arminio Monforte, Antonella, De Luca, Andrea (ORCID:0000-0002-8311-6935), Castagna, Antonella, Monno, Laura, Carta, Stefania, Galli, Laura, Carrara, Stefania, Fedele, Valentina, Punzi, Grazia, Fanti, Iuri, Caramello, Pietro, Lepri, Alessandro Cozzi, De Luca, Andrea, Ceccherini Silberstein, Francesca, D'Arminio Monforte, Antonella, and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Dynamics of human immunodeficiency virus type 1 (HIV-1) tropism after antiretroviral therapy (ART) initiation and their association with disease progression are poorly investigated. This was a cohort study on subjects from the ICONA cohort receiving ART with persistently detectable (PD) or persistently undetectable (PU) viral load (VL) and with stored plasma or peripheral blood mononuclear cell (PBMC) samples at 2 time-points (T1, T2) after ART initiation. HIV-1 co-receptor tropism was determined by V3-loop sequencing and the geno2pheno algorithm. A switch in viral tropism was defined if the tropism classification at T2 differed from that observed at T1. Time to disease progression, defined as the occurrence of a new acquired immune deficiency syndrome (AIDS)-defining event/death from T2, was also evaluated. One hundred ninety-five patients were analyzed (124 PD, 71 PU). Over a median follow-up of 22.6 (19.8-28.1) months, PD and PU patients showed similar rates (95% confidence interval) of switch to a non-R5 virus [PD: 6.9 (3.7-11.2)/100-person-years of follow-up (PYFU); PU: 8.0 (3.4-14.5)/100-PYFU; P=0.63] and of switch to a R5 virus [PD: 15.4 (7.3-26.4)/100-PYFU; PU: 8.1 (2.5-16.7)/100-PYFU; P=0.38]. Switch to non-R5 virus was predicted by nadir CD4+ before T1. Twenty-two (18%) PD and 4 (6%) PU subjects experienced disease progression (P=0.02). The risk of disease progression was independently associated with a switch in co-receptor tropism (adjusted hazard ratio=4.06, 95% CI: 1.20-13.80, P=0.03) as well as age, AIDS diagnosis, nadir CD4+ before T2, current CD4+, and VL. Switch of HIV-1 tropism under ART occurs in both directions, with similar rates in subjects with PD or PU VL and it might be predictive of future unfavorable clinical outcome.
Published: 2016

26. Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients

Author: Fabbiani, Massimiliano, Di Giambenedetto, Simona, Poli, Andrea, Borghetti, Alberto, Castagna, Antonella, Mondi, Annalisa, Galizzi, Nadia, Maillard, Myriam, Gori, Andrea, Cauda, Roberto, De Luca, Andrea, Gianotti, Nicola, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Fabbiani, Massimiliano, Di Giambenedetto, Simona, Poli, Andrea, Borghetti, Alberto, Castagna, Antonella, Mondi, Annalisa, Galizzi, Nadia, Maillard, Myriam, Gori, Andrea, Cauda, Roberto, De Luca, Andrea, Gianotti, Nicola, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Cauda, Roberto (ORCID:0000-0002-1498-4229), and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: not available
Published: 2016

27. Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection

Author: Fabbiani, Massimiliano, Di Giambenedetto, Simona, Cingolani, Antonella, Fanti, Iuri, Colafigli, Manuela, Tamburrini, Enrica, Cauda, Roberto, Navarra, Pierluigi, De Luca, Andrea, Murri, Rita, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Cingolani, Antonella (ORCID:0000-0002-3793-2755), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), Cauda, Roberto (ORCID:0000-0002-1498-4229), Navarra, Pierluigi (ORCID:0000-0002-4424-650X), De Luca, Andrea (ORCID:0000-0002-8311-6935), Murri, Rita (ORCID:0000-0003-4263-7854), Fabbiani, Massimiliano, Di Giambenedetto, Simona, Cingolani, Antonella, Fanti, Iuri, Colafigli, Manuela, Tamburrini, Enrica, Cauda, Roberto, Navarra, Pierluigi, De Luca, Andrea, Murri, Rita, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Cingolani, Antonella (ORCID:0000-0002-3793-2755), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), Cauda, Roberto (ORCID:0000-0002-1498-4229), Navarra, Pierluigi (ORCID:0000-0002-4424-650X), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Murri, Rita (ORCID:0000-0003-4263-7854)
Abstract: The aim of the study was to explore relationships between self-reported adherence, antiretroviral drug concentration measurement (TDM) and self-reported symptoms.
Published: 2016

28. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe

Author: Hofstra, L. Marije, Sauvageot, Nicola, Albert, Jan, Alexiev, Ivailo, Garcia, Federico, Struck, Daniel, Van De Vijver, D. A. M. C., Åsjö, Birgitta, Beshkov, Danail, Coughlan, Suzie, Descamps, Diane, Griskevicius, Algirda, Hamouda, Osamah, Horban, Andrzej, Van Kasteren, Marjo, Kolupajeva, Tatjana, Kostrikis, Leontios G., Liitsola, Kirsi, Linka, Marek, Mor, Orna, Nielsen, Clau, Otelea, Dan, Paraskevis, Dimitrio, Paredes, Roger, Poljak, Mario, Puchhammer Stöckl, Elisabeth, Sönnerborg, Ander, Staneková, Danica, Stanojevic, Maja, Van Laethem, Kristel, Zazzi, Maurizio, Lepej, Snjezana Zidovec, Boucher, Charles A. B., Schmit, Jean Claude, Wensing, Annemarie M. J, Puchhammer Stockl, E., Sarcletti, M., Schmied, B., Geit, M., Balluch, G., Vandamme, A. M., Vercauteren, J., Derdelinckx, I., Sasse, A., Bogaert, M., Ceunen, H., De Roo, A., De Wit, S., Echahidi, F., Fransen, K., Goffard, J. C., Goubau, P., Goudeseune, E., Yombi, J. C., Lacor, P., Liesnard, C., Moutschen, M., Pierard, D., Rens, R., Schrooten, Y., Vaira, D., Vandekerckhove, L. P. R., Van Den Heuvel, A., Van Der Gucht, B., Van Ranst, M., Van Wijngaerden, E., Vandercam, B., Vekemans, M., Verhofstede, C., Clumeck, N., Van Laethem, K., Beshkov, D., Alexiev, I., Lepej, S. Zidovec, Begovac, J., Demetriades, I., Kousiappa, I., Demetriou, V., Hezka, J., Linka, M., Maly, M., Machala, L., Nielsen, C., Jørgensen, L. B., Gerstoft, J., Mathiesen, L., Pedersen, C., Nielsen, H., Laursen, A., Kvinesdal, B., Liitsola, K., Ristola, M., Suni, J., Sutinen, J., Descamps, D., Assoumou, L., Castor, G., Grude, M., Flandre, P., Storto, A., Hamouda, O., Kücherer, C., Berg, T., Braun, P., Poggensee, G., Däumer, M., Eberle, J., Heiken, H., Kaiser, R., Knechten, H., Korn, K., Müller, H., Neifer, S., Schmidt, B., Walter, H., Gunsenheimer Bartmeyer, B., Harrer, T., Paraskevis, D., Hatzakis, A., Zavitsanou, A., Vassilakis, A., Lazanas, M., Chini, M., Lioni, A., Sakka, V., Kourkounti, S., Paparizos, V., Antoniadou, A., Papadopoulos, A., Poulakou, G., Katsarolis, I., Protopapas, K., Chryssos, G., Drimis, S., Gargalianos, P., Xylomenos, G., Lourida, G., Psichogiou, M., Daikos, G. L., Sipsas, N. V., Kontos, A., Gamaletsou, M. N., Koratzanis, G., Sambatakou, E., Mariolis, H., Skoutelis, A., Papastamopoulos, V., Georgiou, O., Panagopoulos, P., Maltezos, E., Coughlan, S., De Gascun, C., Byrne, C., Duffy, M., Bergin, C., Reidy, D., Farrell, G., Lambert, J., O'Connor, E., Rochford, A., Low, J., Coakely, P., O'Dea, S., Hall, W., Mor, O., Levi, I., Chemtob, D., Grossman, Z., Zazzi, M., De Luca, Andrea, Balotta, C., Riva, C., Mussini, C., Caramma, I., Capetti, A., Colombo, M. C., Rossi, C., Prati, F., Tramuto, F., Vitale, F., Ciccozzi, M., Angarano, G., Rezza, G., Kolupajeva, T., Vasins, O., Griskevicius, A., Lipnickiene, V., Schmit, J. C., Struck, D., Sauvageot, N., Hemmer, R., Arendt, V., Michaux, C., Staub, T., Sequin Devaux, C., Wensing, A. M. J., Boucher, C. A. B., Van Kessel, A., Van Bentum, P. H. M., Brinkman, K., Connell, B. J., Van Der Ende, M. E., Hoepelman, I. M., Van Kasteren, M., Kuipers, M., Langebeek, N., Richter, C., Santegoets, R. M. W. J., Schrijnders Gudde, L., Schuurman, R., Van De Ven, B. J. M., Åsjö, B., Kran, A. M. Bakken, Ormaasen, V., Aavitsland, P., Horban, A., Stanczak, J. J., Stanczak, G. P., Firlag Burkacka, E., Wiercinska Drapalo, A., Jablonowska, E., Maolepsza, E., Leszczyszyn Pynka, M., Szata, W., Camacho, R., Palma, C., Borges, F., Paixão, T., Duque, V., Araújo, F., Otelea, D., Paraschiv, S., Tudor, A. M., Cernat, R., Chiriac, C., Dumitrescu, F., Prisecariu, L. J., Stanojevic, M., Jevtovic, D. j., Salemovic, D., Stanekova, D., Habekova, M., Chabadová, Z., Drobkova, T., Bukovinova, P., Shunnar, A., Truska, P., Poljak, M., Lunar, M., Babic, D., Tomazic, J., Vidmar, L., Vovko, T., Karner, P., Garcia, F., Paredes, R., Monge, S., Moreno, S., Del Amo, J., Asensi, V., Sirvent, J. L., De Mendoza, C., Delgado, R., Gutiérrez, F., Berenguer, J., Garcia Bujalance, S., Stella, N., De Los Santos, I., Blanco, J. R., Dalmau, D., Rivero, M., Segura, F., Elías, M. J. Pérez, Alvarez, M., Chueca, N., Rodríguez Martín, C., Vidal, C., Palomares, J. C., Viciana, I., Viciana, P., Cordoba, J., Aguilera, A., Domingo, P., Galindo, M. J., Miralles, C., Del Pozo, M. A., Ribera, Elena, Iribarren, J. A., Ruiz, L., De La Torre, J., Vidal, F., Clotet, B., Albert, J., Heidarian, A., Aperia Peipke, K., Axelsson, M., Mild, M., Karlsson, A., Sönnerborg, A., Thalme, A., Navér, L., Bratt, G., Blaxhult, A., Gisslén, M., Svennerholm, B., Bergbrant, I., Björkman, P., Säll, C., Mellgren, Å., Lindholm, A., Kuylenstierna, N., Montelius, R., Azimi, F., Johansson, B., Carlsson, M., Johansson, E., Ljungberg, B., Ekvall, H., Strand, A., Mäkitalo, S., Öberg, S., Holmblad, P., Höfer, M., Holmberg, H., Josefson, P., Ryding, U., De Luca, Andrea (ORCID:0000-0002-8311-6935), Hofstra, L. Marije, Sauvageot, Nicola, Albert, Jan, Alexiev, Ivailo, Garcia, Federico, Struck, Daniel, Van De Vijver, D. A. M. C., Åsjö, Birgitta, Beshkov, Danail, Coughlan, Suzie, Descamps, Diane, Griskevicius, Algirda, Hamouda, Osamah, Horban, Andrzej, Van Kasteren, Marjo, Kolupajeva, Tatjana, Kostrikis, Leontios G., Liitsola, Kirsi, Linka, Marek, Mor, Orna, Nielsen, Clau, Otelea, Dan, Paraskevis, Dimitrio, Paredes, Roger, Poljak, Mario, Puchhammer Stöckl, Elisabeth, Sönnerborg, Ander, Staneková, Danica, Stanojevic, Maja, Van Laethem, Kristel, Zazzi, Maurizio, Lepej, Snjezana Zidovec, Boucher, Charles A. B., Schmit, Jean Claude, Wensing, Annemarie M. J, Puchhammer Stockl, E., Sarcletti, M., Schmied, B., Geit, M., Balluch, G., Vandamme, A. M., Vercauteren, J., Derdelinckx, I., Sasse, A., Bogaert, M., Ceunen, H., De Roo, A., De Wit, S., Echahidi, F., Fransen, K., Goffard, J. C., Goubau, P., Goudeseune, E., Yombi, J. C., Lacor, P., Liesnard, C., Moutschen, M., Pierard, D., Rens, R., Schrooten, Y., Vaira, D., Vandekerckhove, L. P. R., Van Den Heuvel, A., Van Der Gucht, B., Van Ranst, M., Van Wijngaerden, E., Vandercam, B., Vekemans, M., Verhofstede, C., Clumeck, N., Van Laethem, K., Beshkov, D., Alexiev, I., Lepej, S. Zidovec, Begovac, J., Demetriades, I., Kousiappa, I., Demetriou, V., Hezka, J., Linka, M., Maly, M., Machala, L., Nielsen, C., Jørgensen, L. B., Gerstoft, J., Mathiesen, L., Pedersen, C., Nielsen, H., Laursen, A., Kvinesdal, B., Liitsola, K., Ristola, M., Suni, J., Sutinen, J., Descamps, D., Assoumou, L., Castor, G., Grude, M., Flandre, P., Storto, A., Hamouda, O., Kücherer, C., Berg, T., Braun, P., Poggensee, G., Däumer, M., Eberle, J., Heiken, H., Kaiser, R., Knechten, H., Korn, K., Müller, H., Neifer, S., Schmidt, B., Walter, H., Gunsenheimer Bartmeyer, B., Harrer, T., Paraskevis, D., Hatzakis, A., Zavitsanou, A., Vassilakis, A., Lazanas, M., Chini, M., Lioni, A., Sakka, V., Kourkounti, S., Paparizos, V., Antoniadou, A., Papadopoulos, A., Poulakou, G., Katsarolis, I., Protopapas, K., Chryssos, G., Drimis, S., Gargalianos, P., Xylomenos, G., Lourida, G., Psichogiou, M., Daikos, G. L., Sipsas, N. V., Kontos, A., Gamaletsou, M. N., Koratzanis, G., Sambatakou, E., Mariolis, H., Skoutelis, A., Papastamopoulos, V., Georgiou, O., Panagopoulos, P., Maltezos, E., Coughlan, S., De Gascun, C., Byrne, C., Duffy, M., Bergin, C., Reidy, D., Farrell, G., Lambert, J., O'Connor, E., Rochford, A., Low, J., Coakely, P., O'Dea, S., Hall, W., Mor, O., Levi, I., Chemtob, D., Grossman, Z., Zazzi, M., De Luca, Andrea, Balotta, C., Riva, C., Mussini, C., Caramma, I., Capetti, A., Colombo, M. C., Rossi, C., Prati, F., Tramuto, F., Vitale, F., Ciccozzi, M., Angarano, G., Rezza, G., Kolupajeva, T., Vasins, O., Griskevicius, A., Lipnickiene, V., Schmit, J. C., Struck, D., Sauvageot, N., Hemmer, R., Arendt, V., Michaux, C., Staub, T., Sequin Devaux, C., Wensing, A. M. J., Boucher, C. A. B., Van Kessel, A., Van Bentum, P. H. M., Brinkman, K., Connell, B. J., Van Der Ende, M. E., Hoepelman, I. M., Van Kasteren, M., Kuipers, M., Langebeek, N., Richter, C., Santegoets, R. M. W. J., Schrijnders Gudde, L., Schuurman, R., Van De Ven, B. J. M., Åsjö, B., Kran, A. M. Bakken, Ormaasen, V., Aavitsland, P., Horban, A., Stanczak, J. J., Stanczak, G. P., Firlag Burkacka, E., Wiercinska Drapalo, A., Jablonowska, E., Maolepsza, E., Leszczyszyn Pynka, M., Szata, W., Camacho, R., Palma, C., Borges, F., Paixão, T., Duque, V., Araújo, F., Otelea, D., Paraschiv, S., Tudor, A. M., Cernat, R., Chiriac, C., Dumitrescu, F., Prisecariu, L. J., Stanojevic, M., Jevtovic, D. j., Salemovic, D., Stanekova, D., Habekova, M., Chabadová, Z., Drobkova, T., Bukovinova, P., Shunnar, A., Truska, P., Poljak, M., Lunar, M., Babic, D., Tomazic, J., Vidmar, L., Vovko, T., Karner, P., Garcia, F., Paredes, R., Monge, S., Moreno, S., Del Amo, J., Asensi, V., Sirvent, J. L., De Mendoza, C., Delgado, R., Gutiérrez, F., Berenguer, J., Garcia Bujalance, S., Stella, N., De Los Santos, I., Blanco, J. R., Dalmau, D., Rivero, M., Segura, F., Elías, M. J. Pérez, Alvarez, M., Chueca, N., Rodríguez Martín, C., Vidal, C., Palomares, J. C., Viciana, I., Viciana, P., Cordoba, J., Aguilera, A., Domingo, P., Galindo, M. J., Miralles, C., Del Pozo, M. A., Ribera, Elena, Iribarren, J. A., Ruiz, L., De La Torre, J., Vidal, F., Clotet, B., Albert, J., Heidarian, A., Aperia Peipke, K., Axelsson, M., Mild, M., Karlsson, A., Sönnerborg, A., Thalme, A., Navér, L., Bratt, G., Blaxhult, A., Gisslén, M., Svennerholm, B., Bergbrant, I., Björkman, P., Säll, C., Mellgren, Å., Lindholm, A., Kuylenstierna, N., Montelius, R., Azimi, F., Johansson, B., Carlsson, M., Johansson, E., Ljungberg, B., Ekvall, H., Strand, A., Mäkitalo, S., Öberg, S., Holmblad, P., Höfer, M., Holmberg, H., Josefson, P., Ryding, U., and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. Methods. Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. Results. The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%-9.5%) in 2008-2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. Conclusions. Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.
Published: 2016

29. Listeria meningoencephalitis and anti-GQ1b antibody syndrome

Author: Vergori, A., Masi, G., Donati, D., Ginanneschi, F., Annunziata, P., Cerase, A., Mencarelli, M., Rossetti, Barbara, De Luca, Andrea, Zanelli, G., De Luca, Andrea (ORCID:0000-0002-8311-6935), Vergori, A., Masi, G., Donati, D., Ginanneschi, F., Annunziata, P., Cerase, A., Mencarelli, M., Rossetti, Barbara, De Luca, Andrea, Zanelli, G., and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: We report the first case of Listeria monocytogenes meningoencephalitis associated with anti-GQ1b antibody syndrome in an immunocompetent adult. A prompt diagnosis, made thanks to the multidisciplinary contribution, allowed a combined therapeutic approach leading to final favourable outcome, despite several intercurrent complications.
Published: 2016

30. Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study

Author: Lombardi, Francesca, Belmonti, Simone, Fabbiani, Massimiliano, Borghetti, Alberto, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Lombardi, Francesca, Belmonti, Simone, Fabbiani, Massimiliano, Borghetti, Alberto, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Lombardi, Francesca (ORCID:0000-0001-5757-8346), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: not available
Published: 2016

31. Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy

Author: Borghetti, Alberto, Baldin, Gianmaria, Ciccullo, Arturo, Gagliardini, Roberta, D'Avino, Alessandro, Mondi, Annalisa, Ciccarelli, Nicoletta, Lamonica, Silvia, Fanti, Iuri, Trecarichi, Enrico Maria, Fabbiani, Massimiliano, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Borghetti, Alberto, Baldin, Gianmaria, Ciccullo, Arturo, Gagliardini, Roberta, D'Avino, Alessandro, Mondi, Annalisa, Ciccarelli, Nicoletta, Lamonica, Silvia, Fanti, Iuri, Trecarichi, Enrico Maria, Fabbiani, Massimiliano, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: Not Available
Published: 2016

32. Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients

Author: Gagliardini, Roberta, Fabbiani, Massimiliano, Colafigli, Manuela, D'Avino, Alessandro, Mondi, Annalisa, Borghetti, Alberto, Lamonica, Silvia, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Gagliardini, Roberta, Fabbiani, Massimiliano, Colafigli, Manuela, D'Avino, Alessandro, Mondi, Annalisa, Borghetti, Alberto, Lamonica, Silvia, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: Tenofovir could have a direct lipid-lowering effect. The aim of our retrospective study was to investigate changes in cardiovascular risk after switching from a tenofovir-sparing to a tenofovir-containing backbone. Lipid parameters and cardiovascular risk [calculated using 10-years Framingham Risk Score (FRS) and 5-years DAD Risk Score (DRS)] were analysed at baseline and after three months. 273 patients were enrolled. After switching, significant decreases in total cholesterol (TC) (–8.2mg/dl, p < 0.001), LDL (–8.7mg/dl, p < 0.001) and DRS (mean –0.26%, p < 0.001) were observed, while a reduction in FRS was only observed in patients with pre-switch high TC or medium-high (>10%) FRS. Pre-switch factors associated with DRS reduction were higher TC, abacavir, new generation protease inhibitors, while zidovudine predicted an increase of DRS. Our results suggest that the improvement of lipid parameters observed after switching to a tenofovir-containing backbone could lead to a significant reduction in predicted cardiovascular risk, which became more evident in subjects with higher cardiovascular risk.
Published: 2016

33. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program

Author: Massimo, Andreoni, Teti, Elisabetta, Antinori, Andrea, Milazzoi, Laura, Sollima, Savatore, Rizzardini, Giuliano, Di Biagio, Antonio, Saracino, Annalisa, Bruno, Raffaele, Borghi, Vanni, De Luca, Andrea, Cattelan, Annamaria, Hasson, Hamid, Taliani, Gloria, Monforte, Antonella D'Arminio, Mastroianni, Claudio Maria, Di Perri, Giovanni, Bigoni, Sara, Puoti, Massimo, Spinetti, Angiola, Gori, Andrea, Boffa, Nicola, Bruno, Cacopardo, Giacometti, Andrea, Parruti, Giustino, Vullo, Vincenzo, Chirianni, Antonio, Pennica, Alfredo, Pasquazzi, Caterina, Segala, Daniela, Sarmati, Loredana, De Luca, Andrea (ORCID:0000-0002-8311-6935), Massimo, Andreoni, Teti, Elisabetta, Antinori, Andrea, Milazzoi, Laura, Sollima, Savatore, Rizzardini, Giuliano, Di Biagio, Antonio, Saracino, Annalisa, Bruno, Raffaele, Borghi, Vanni, De Luca, Andrea, Cattelan, Annamaria, Hasson, Hamid, Taliani, Gloria, Monforte, Antonella D'Arminio, Mastroianni, Claudio Maria, Di Perri, Giovanni, Bigoni, Sara, Puoti, Massimo, Spinetti, Angiola, Gori, Andrea, Boffa, Nicola, Bruno, Cacopardo, Giacometti, Andrea, Parruti, Giustino, Vullo, Vincenzo, Chirianni, Antonio, Pennica, Alfredo, Pasquazzi, Caterina, Segala, Daniela, Sarmati, Loredana, and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: not available
Published: 2016

34. The global spread of HIV-1 subtype B epidemic

Author: Magiorkinis, Gkika, Angelis, Konstantino, Mamais, Ioanni, Katzourakis, Ari, Hatzakis, Angelo, Albert, Jan, Lawyer, Glenn, Hamouda, Osamah, Struck, Daniel, Vercauteren, Jurgen, Wensing, Annemarie, Alexiev, Ivailo, Åsjö, Birgitta, Balotta, Claudia, Gomes, Perpétua, Camacho, Ricardo J., Coughlan, Suzie, Griskevicius, Algirda, Grossman, Zehava, Horban, Ander, Kostrikis, Leondios G., Lepej, Snjezana J., Liitsola, Kirsi, Linka, Marek, Nielsen, Clau, Otelea, Dan, Paredes, Roger, Poljak, Mario, Puchhammer Stöckl, Elizabeth, Schmit, Jean Claude, Sönnerborg, Ander, Staneková, Danica, Stanojevic, Maja, Stylianou, Dora C., Boucher, Charles A. B., Nikolopoulos, Georgio, Vasylyeva, Tetyana, Friedman, Samuel R., van de Vijver, David, Angarano, Gioacchino, Chaix, Marie Laure, De Luca, Andrea, Korn, Klau, Loveday, Clive, Soriano, Vincent, Yerly, Sabine, Zazzi, Mauricio, Vandamme, Anne Mieke, Paraskevis, Dimitrios, De Luca, Andrea (ORCID:0000-0002-8311-6935), Magiorkinis, Gkika, Angelis, Konstantino, Mamais, Ioanni, Katzourakis, Ari, Hatzakis, Angelo, Albert, Jan, Lawyer, Glenn, Hamouda, Osamah, Struck, Daniel, Vercauteren, Jurgen, Wensing, Annemarie, Alexiev, Ivailo, Åsjö, Birgitta, Balotta, Claudia, Gomes, Perpétua, Camacho, Ricardo J., Coughlan, Suzie, Griskevicius, Algirda, Grossman, Zehava, Horban, Ander, Kostrikis, Leondios G., Lepej, Snjezana J., Liitsola, Kirsi, Linka, Marek, Nielsen, Clau, Otelea, Dan, Paredes, Roger, Poljak, Mario, Puchhammer Stöckl, Elizabeth, Schmit, Jean Claude, Sönnerborg, Ander, Staneková, Danica, Stanojevic, Maja, Stylianou, Dora C., Boucher, Charles A. B., Nikolopoulos, Georgio, Vasylyeva, Tetyana, Friedman, Samuel R., van de Vijver, David, Angarano, Gioacchino, Chaix, Marie Laure, De Luca, Andrea, Korn, Klau, Loveday, Clive, Soriano, Vincent, Yerly, Sabine, Zazzi, Mauricio, Vandamme, Anne Mieke, Paraskevis, Dimitrios, and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Human immunodeficiency virus type 1 (HIV-1) was discovered in the early 1980s when the virus had already established a pandemic. For at least three decades the epidemic in the Western World has been dominated by subtype B infections, as part of a sub-epidemic that traveled from Africa through Haiti to United States. However, the pattern of the subsequent spread still remains poorly understood. Here we analyze a large dataset of globally representative HIV-1 subtype B strains to map their spread around the world over the last 50 years and describe significant spread patterns. We show that subtype B travelled from North America to Western Europe in different occasions, while Central/Eastern Europe remained isolated for the most part of the early epidemic. Looking with more detail in European countries we see that the United Kingdom, France and Switzerland exchanged viral isolates with non-European countries than with European ones. The observed pattern is likely to mirror geopolitical landmarks in the post-World War II era, namely the rise and the fall of the Iron Curtain and the European colonialism. In conclusion, HIV-1 spread through specific migration routes which are consistent with geopolitical factors that affected human activities during the last 50 years, such as migration, tourism and trade. Our findings support the argument that epidemic control policies should be global and incorporate political and socioeconomic factors.
Published: 2016

35. Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort

Author: D'Arminio Monforte, Antonella, Cozzi Lepri, Alessandro, Maggiolo, Franco, Rizzardini, Giuliano, Manconi, Paolo Emilio, Gianotti, Nicola, Quirino, Tiziana, Pinnetti, Carmela, Rusconi, Stefano, De Luca, Andrea, Antinori, Andrea, Andreoni, M., Angarano, G., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., Von Schloesser, F., Viale, P., Castagna, A., Ceccherini Silberstein, F., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Bonora, S., Borderi, M., Calcagno, A., Calza, L., Capobianchi, M. R., Cingolani, Antonella, Cinque, P., Di Biagio, A., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Marchetti, G., Marcotullio, S., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Santoro, M. M., Saracino, A., Zaccarelli, M., Fanti, Iuri, Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Tavelli, A., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, A., Costantini, A., Valeriani, C., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Abeli, C., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Vichi, F., Cassola, G., Viscoli, C., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Di Martino, F., Maddaloni, L., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Antinori, A., Vullo, V., Cristaudo, A., Cingolani, A., Baldin, Gianmaria, Cicalini, S., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Savinelli, S., Latini, A., Cecchetto, M., Viviani, F., Mura, M. S., Rossetti, Barbara, Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., De Luca, Andrea (ORCID:0000-0002-8311-6935), Cauda, R. (ORCID:0000-0002-1498-4229), Cingolani, Antonella (ORCID:0000-0002-3793-2755), D'Arminio Monforte, Antonella, Cozzi Lepri, Alessandro, Maggiolo, Franco, Rizzardini, Giuliano, Manconi, Paolo Emilio, Gianotti, Nicola, Quirino, Tiziana, Pinnetti, Carmela, Rusconi, Stefano, De Luca, Andrea, Antinori, Andrea, Andreoni, M., Angarano, G., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., Von Schloesser, F., Viale, P., Castagna, A., Ceccherini Silberstein, F., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Bonora, S., Borderi, M., Calcagno, A., Calza, L., Capobianchi, M. R., Cingolani, Antonella, Cinque, P., Di Biagio, A., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Marchetti, G., Marcotullio, S., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Santoro, M. M., Saracino, A., Zaccarelli, M., Fanti, Iuri, Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Tavelli, A., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, A., Costantini, A., Valeriani, C., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Abeli, C., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Vichi, F., Cassola, G., Viscoli, C., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Di Martino, F., Maddaloni, L., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Antinori, A., Vullo, V., Cristaudo, A., Cingolani, A., Baldin, Gianmaria, Cicalini, S., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Savinelli, S., Latini, A., Cecchetto, M., Viviani, F., Mura, M. S., Rossetti, Barbara, Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., De Luca, Andrea (ORCID:0000-0002-8311-6935), Cauda, R. (ORCID:0000-0002-1498-4229), and Cingolani, Antonella (ORCID:0000-0002-3793-2755)
Abstract: Background There are no data comparing the response to PI/r-based regimens in people presenting for care with low CD4 counts or AIDS (LC). Aim To compare the response to LPV/r-, DRV/r- or ATV/r-based cART regimens in LC initiating cART from ART-naive. Methods We included people enrolled in Icona with either CD4 counts ≤350 cells/mm3 (low CD4-LC) or CD4 counts ≤200 cells/mm3 (very low CD4-VLC) and/or AIDS, starting their first PI/rbased regimen after 2008. Initial regimens were compared by intention-to-treat: i) time to viral failure (VF) (first of 2 consecutive VL>200 copies/mL after ≥6 months); II) time to PI/r discontinuation/switching for any cause (TD) and for toxicity (TDT); III) treatment failure (TF) (VF or TD). Kaplan-Meier and Cox analyses were used. Results 1,362 LC patients were included (DRV/r 607; ATV/r 552; LPV/r 203); 813 VLC. In a median of 18 months (IQR:7-35), the 1-year probability of VF and TF were 2.8% (1.9-3.8) and 21.1% (18.7-23.4). In the adjusted analysis, patients initiating ATV/r had a 53% lower chance, and those initiating DRV/r a 61% lower chance of TD, as compared to LPV/r; the risk of TF was more likely in people starting LPV/r. Results were similar among VLC; in this subgroup LPV/r including regimens demonstrated a lower chance of VF. Conclusions We confirmed in LC a low chance of virological failure by 1 year, with small differences according to PI/r. However, larger differences were observed when comparing longer-term endpoints such as treatment failure. These results are important for people presenting late for care.
Published: 2016

36. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen

Author: De Luca, Andrea, Flandre, Philippe, Dunn, David, Zazzi, Maurizio, Wensing, Annemarie, Santoro, Maria Mercede, Günthard, Huldrych F, Wittkop, Linda, Kordossis, Theodoro, Garcia, Federico, Castagna, Antonella, Cozzi Lepri, Alessandro, Churchill, Duncan, De Wit, Stéphane, Brockmeyer, Norbert H, Imaz, Arkaitz, Mussini, Cristina, Obel, Niel, Perno, Carlo Federico, Roca, Bernardino, Reiss, Peter, Schülter, Eugen, Torti, Carlo, Van Sighem, Ard, Zangerle, Robert, Descamps, Diane, De Luca, Andrea (ORCID:0000-0002-8311-6935), De Luca, Andrea, Flandre, Philippe, Dunn, David, Zazzi, Maurizio, Wensing, Annemarie, Santoro, Maria Mercede, Günthard, Huldrych F, Wittkop, Linda, Kordossis, Theodoro, Garcia, Federico, Castagna, Antonella, Cozzi Lepri, Alessandro, Churchill, Duncan, De Wit, Stéphane, Brockmeyer, Norbert H, Imaz, Arkaitz, Mussini, Cristina, Obel, Niel, Perno, Carlo Federico, Roca, Bernardino, Reiss, Peter, Schülter, Eugen, Torti, Carlo, Van Sighem, Ard, Zangerle, Robert, Descamps, Diane, and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: OBJECTIVES: The objective of this study was to improve the prediction of the impact of HIV-1 protease mutations in different viral subtypes on virological response to darunavir. METHODS: Darunavir-containing treatment change episodes (TCEs) in patients previously failing PIs were selected from large European databases. HIV-1 subtype B-infected patients were used as the derivation dataset and HIV-1 non-B-infected patients were used as the validation dataset. The adjusted association of each mutation with week 8 HIV RNA change from baseline was analysed by linear regression. A prediction model was derived based on best subset least squares estimation with mutational weights corresponding to regression coefficients. Virological outcome prediction accuracy was compared with that from existing genotypic resistance interpretation systems (GISs) (ANRS 2013, Rega 9.1.0 and HIVdb 7.0). RESULTS: TCEs were selected from 681 subtype B-infected and 199 non-B-infected adults. Accompanying drugs were NRTIs in 87%, NNRTIs in 27% and raltegravir or maraviroc or enfuvirtide in 53%. The prediction model included weighted protease mutations, HIV RNA, CD4 and activity of accompanying drugs. The model's association with week 8 HIV RNA change in the subtype B (derivation) set was R(2) = 0.47 [average squared error (ASE) = 0.67, P < 10(-6)]; in the non-B (validation) set, ASE was 0.91. Accuracy investigated by means of area under the receiver operating characteristic curves with a binary response (above the threshold value of HIV RNA reduction) showed that our final model outperformed models with existing interpretation systems in both training and validation sets. CONCLUSIONS: A model with a new darunavir-weighted mutation score outperformed existing GISs in both B and non-B subtypes in predicting virological response to darunavir.
Published: 2016

37. Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen

Author: Fabbiani, Massimiliano, Zaccarelli, M, Latini, A, Sterrantino, G, D'Ettorre, G, Grima, P, Mondi, Annalisa, Rossetti, Barbara, Borchi, B, Giuliani, M, Antinori, A, De Luca, Andrea, Di Giambenedetto, Simona, De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Fabbiani, Massimiliano, Zaccarelli, M, Latini, A, Sterrantino, G, D'Ettorre, G, Grima, P, Mondi, Annalisa, Rossetti, Barbara, Borchi, B, Giuliani, M, Antinori, A, De Luca, Andrea, Di Giambenedetto, Simona, De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: Despite not being approved in Europe as first-line therapy, the efavirenz (EFV)-containing single tablet regimen (STR) is frequently used in clinical practice in naïve patients but few data are available on this strategy. In our study, we aimed to assess the risk of EFV discontinuation in patients starting antiretroviral therapy with STR vs. nonSTR.
Published: 2015

38. Case report: Persistent strongyloidiasis complicated by recurrent meningitis in an HTLV seropositive Peruvian migrant resettled in Italy

Author: Zammarchi, Lorenzo, Montagnani, Francesca, Tordini, Giacinta, Gotuzzo, Eduardo, Bisoffi, Zeno, Bartoloni, Alessandro, De Luca, Andrea, De Luca, Andrea (ORCID:0000-0002-8311-6935), Zammarchi, Lorenzo, Montagnani, Francesca, Tordini, Giacinta, Gotuzzo, Eduardo, Bisoffi, Zeno, Bartoloni, Alessandro, De Luca, Andrea, and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: We describe a case of persistent strongyloidiasis complicated by recurrent meningitis, in a human T cell lymphotropic virus type 1 (HTLV-1) seropositive Peruvian migrant adult resettled in Italy. He was admitted with signs and symptoms of acute bacterial meningitis, reporting four other meningitis episodes in the past 6 years, with an etiological diagnosis of Escherichia coli and Enterococcus faecium in two cases. He had been previously treated with several antihelmintic regimens not including ivermectin, without eradication of strongyloidiasis, and he had never been tested for HTLV before. During the described episode, the patient was treated for meningitis with broad-spectrum antibiotic therapy and 200 mg/kg/dose oral ivermectin once daily on day 1, 2, 15 and 16 with full recovery and no further episodes of meningitis. The presented case underlines several critical points concerning the management of poorly known neglected diseases such as strongyloidiasis and HTLV infection in low-endemic areas. Despite several admissions for meningitis and strongyloidiasis, the parasitic infection was not adequately treated and the patient was not previously tested for HTLV. The supply of ivermectin and the choice of treatment scheme was challenging since ivermectin is not approved in Italy and there are no standardized guidelines for the treatment of severe strongyloidiasis in HTLV seropositive subjects.
Published: 2015

39. Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients

Author: Lichtner, M, Cicconi, P, Vita, S, Cozzi Lepri, A, Galli, M, Lo Caputo, S, Saracino, A, De Luca, Andrea, Moioli, M, Maggiolo, F, Marchetti, G, Vullo, V, D'Arminio Monforte, A., De Luca, Andrea (ORCID:0000-0002-8311-6935), Lichtner, M, Cicconi, P, Vita, S, Cozzi Lepri, A, Galli, M, Lo Caputo, S, Saracino, A, De Luca, Andrea, Moioli, M, Maggiolo, F, Marchetti, G, Vullo, V, D'Arminio Monforte, A., and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Chronic cytomegalovirus (CMV) infection has been associated with immunosenescence and immunoactivation in the general population. In human immunodeficiency virus type 1 (HIV-1)-infected people, CMV coinfection, in addition to residual HIV replication and microbial translocation, has been proposed as a key factor in sustaining immune activation, even in individuals with a controlled HIV load.
Published: 2015

40. Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors

Author: De Luca, Andrea, Di Giambenedetto, Simona, Lo Presti, A, Sierra, S, Prosperi, M, Cella, E, Giovanetti, M, Torti, C, Caudai, C, Vicenti, I, Saladini, F, Almi, P, Grima, Pierfrancesco, Blanc, P, Fabbiani, Massimiliano, Rossetti, Barbara, Gagliardini, Roberta, Kaiser, R, Ciccozzi, M, Zazzi, M., De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), De Luca, Andrea, Di Giambenedetto, Simona, Lo Presti, A, Sierra, S, Prosperi, M, Cella, E, Giovanetti, M, Torti, C, Caudai, C, Vicenti, I, Saladini, F, Almi, P, Grima, Pierfrancesco, Blanc, P, Fabbiani, Massimiliano, Rossetti, Barbara, Gagliardini, Roberta, Kaiser, R, Ciccozzi, M, Zazzi, M., De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: Background. Hepatitis C virus (HCV) genotype 1 is the most prevalent worldwide. Subtype 1a, compared with 1b, shows lower response rates and higher propensity to select for drug resistance to NS3 and selected NS5A and nonnucleoside NS5B inhibitors. Two distinct clades of subtype 1a have been described. Methods. Using Bayesian methodology, we performed a time-scaled phylogeny reconstruction of clade separation and characterized the geographic distribution, phylodynamics, and association with natural resistance variants of NS3 sequences from 362 patients carrying subtype 1a HCV. Results. All sequences segregated in 2 clearly distinct clades. Clade I showed an earlier origin from the common ancestor compared with clade II. Clade I virus was more prevalent in non-European countries, represented mostly by United States, compared with European (75.7% vs 49.3%; P < .001). The prevalence of the natural NS3 variant Q80K, associated with resistance to the macrocyclic protease inhibitor simeprevir, was detected in 51.6% of clade I and 0% of clade II (P < .001); clade I showed a lower genetic barrier for Q80K, whereas no sign of selective pressure at any protease inhibitor resistance-associated codon was detected. Conclusions. Hepatitis C virus subtype 1a clades have a clearly different distribution in Europe and the United States, and the natural resistance mutation Q80K is exclusively associated with clade I.
Published: 2015

41. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project

Author: Andreoni, M, Marcotullio, S, Puro, V, De Carli, G, Tambussi, G, Nozza, S, Gori, A, Rusconi, S, Santoro, Mm, Clementi, M, Perno, Cf, D'Arminio Monforte, A, Maggiolo, F, Castagna, A, De Luca, Andrea, Galli, M, Giacomelli, A, Borderi, M, Guaraldi, G, Calcagno, A, Di Perri, G, Bonora, S, Mussini, C, Di Biagio, A, Puoti, M, Bruno, R, Zuccaro, V, Antinori, A, Cinque, P, Croce, D, Restelli, U, Rizzardini, G, Lazzarin, A., De Luca, Andrea (ORCID:0000-0002-8311-6935), Andreoni, M, Marcotullio, S, Puro, V, De Carli, G, Tambussi, G, Nozza, S, Gori, A, Rusconi, S, Santoro, Mm, Clementi, M, Perno, Cf, D'Arminio Monforte, A, Maggiolo, F, Castagna, A, De Luca, Andrea, Galli, M, Giacomelli, A, Borderi, M, Guaraldi, G, Calcagno, A, Di Perri, G, Bonora, S, Mussini, C, Di Biagio, A, Puoti, M, Bruno, R, Zuccaro, V, Antinori, A, Cinque, P, Croce, D, Restelli, U, Rizzardini, G, Lazzarin, A., and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Thanks to the development of antiretroviral agents to control HIV replication, HIV infection has turned from a fatal disease into a treatable chronic infection. The present work collects the opinions of several experts on the efficacy and safety of recently approved second generation of integrase inhibitors and, in particular, on the role of this new class of drugs in antiretroviral therapy. The availability of new therapeutic options represents an opportunity to ameliorate the efficacy of cART in controlling HIV replication also within viral reservoirs. The personalization of the treatment driven mainly by the management of comorbidities, HIV-HCV co-infections and aging, will be easier with antiretroviral drugs without drug-drug interactions and with a better toxicity and tolerability profile. Future assessment of economic impact for the introduction of new innovative drugs in the field of antiretroviral therapy will likely need some degree of adjustment of the evaluation criteria of costs and benefit which are currently based almost exclusively on morbidity and mortality.
Published: 2015

42. Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus

Author: Mussini, C, Lorenzini, P, Puoti, M, Lichtner, M, Lapadula, G, Di Giambenedetto, Simona, Antinori, A, Madeddu, G, Cozzi Lepri, A, D'Arminio Monforte, A, De Luca, Andrea, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), De Luca, Andrea (ORCID:0000-0002-8311-6935), Mussini, C, Lorenzini, P, Puoti, M, Lichtner, M, Lapadula, G, Di Giambenedetto, Simona, Antinori, A, Madeddu, G, Cozzi Lepri, A, D'Arminio Monforte, A, De Luca, Andrea, Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: To evaluate the Fibrosis (FIB)-4 index as a predictor of major liver-related events (LRE) and liver-related death (LRD) in human immunodeficiency virus (HIV) type-1 patients initiating combination antiretroviral therapy (cART).
Published: 2015

43. Elimination of Mother-To-Child Transmission of HIV Infection: The Drug Resource Enhancement against AIDS and Malnutrition Model

Author: Liotta, G, Marazzi, Mc, Mothibi, Ke, Zimba, I, Amangoua, Ee, Bonje, Ek, Bossiky, Bnb, Robinson, Pa, Scarcella, P, Musokotwane, K, Palombi, L, Germano, P, Narciso, P, De Luca, Andrea, Alumando, E, Mamary, Sh, Magid, Na, Guidotti, G, Mancinelli, S, Orlando, S, Peroni, M, Buonomo, E, Nielsen Saines, K., De Luca, Andrea (ORCID:0000-0002-8311-6935), Liotta, G, Marazzi, Mc, Mothibi, Ke, Zimba, I, Amangoua, Ee, Bonje, Ek, Bossiky, Bnb, Robinson, Pa, Scarcella, P, Musokotwane, K, Palombi, L, Germano, P, Narciso, P, De Luca, Andrea, Alumando, E, Mamary, Sh, Magid, Na, Guidotti, G, Mancinelli, S, Orlando, S, Peroni, M, Buonomo, E, Nielsen Saines, K., and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: The Drug Resource Enhancement against AIDS and Malnutrition Program (DREAM) gathered professionals in the field of Elimination of HIV-Mother-To-Child Transmission (EMTCT) in Maputo in 2013 to discuss obstacles and solutions for the elimination of HIV vertical transmission in sub-Saharan Africa. During this workshop, the benefits of administrating combined antiretroviral therapy (cART) to HIV positive women from pregnancy throughout breastfeeding were reviewed. cART is capable of reducing vertical transmission to less than 5% at 24 months of age, as well as maternal mortality and infant mortality in both HIV infected and exposed populations to levels similar to those of uninfected individuals. The challenge for programs targeting eMTCT in developing countries is retention in care and treatment adherence. Both are intrinsically related to the model of care. The drop-out from eMTCT programs before cART initiation ranges from 33%-88% while retention rates at 18-24 months are less than 50%. Comprehensive strategies including peer-to-peer education, social support and laboratory monitoring can reduce refusals to less than 5% and attain retention rates approaching 90%. Several components of the model of care for reduction of HIV-1 MTCT are feasible and implementable in scale-up strategies. A review of this model of care for HIV eMTCT is provided.
Published: 2015

44. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe

Author: Swartz, Je, Vandekerckhove, L, Ammerlaan, H, De Vries, Ac, Begovac, J, Bierman, Wfw, Boucher, Cab, Van Der Ende, Me, Grossman, Z, Kaiser, R, Levy, I, Mudrikova, T, Paredes, R, Perez Bercoff, D, Pronk, M, Richter, C, Schmit, Jc, Vercauteren, J, Zazzi, M, Židovec Lepej, S, De Luca, Andrea, Wensing, Amj, De Luca, Andrea (ORCID:0000-0002-8311-6935), Swartz, Je, Vandekerckhove, L, Ammerlaan, H, De Vries, Ac, Begovac, J, Bierman, Wfw, Boucher, Cab, Van Der Ende, Me, Grossman, Z, Kaiser, R, Levy, I, Mudrikova, T, Paredes, R, Perez Bercoff, D, Pronk, M, Richter, C, Schmit, Jc, Vercauteren, J, Zazzi, M, Židovec Lepej, S, De Luca, Andrea, Wensing, Amj, and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: The combination of tenofovir and efavirenz with either lamivudine or emtricitabine (TELE) has proved to be highly effective in clinical trials for first-line treatment of HIV-1 infection. However, limited data are available on its efficacy in routine clinical practice.
Published: 2015

45. Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients

Author: Ciccarelli, Nicoletta, Grima, Pierfrancesco, Fabbiani, Massimiliano, Baldonero, Eleonora, Borghetti, Alberto, Milanini, Benedetta, Limiti, Silio, Colafigli, Manuela, Tamburrini, Enrica, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Ciccarelli, Nicoletta, Grima, Pierfrancesco, Fabbiani, Massimiliano, Baldonero, Eleonora, Borghetti, Alberto, Milanini, Benedetta, Limiti, Silio, Colafigli, Manuela, Tamburrini, Enrica, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: The aim of our study was to better understand the dynamics between cardiovascular risk factors and immunological parameters in the evolution of cognitive performance in HIV+ patients.
Published: 2015

46. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

Author: Mondi, Annalisa, Fabbiani, Massimiliano, Ciccarelli, Nicoletta, Colafigli, Manuela, D'Avino, Alessandro, Borghetti, Alberto, Gagliardini, Roberta, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Mondi, Annalisa, Fabbiani, Massimiliano, Ciccarelli, Nicoletta, Colafigli, Manuela, D'Avino, Alessandro, Borghetti, Alberto, Gagliardini, Roberta, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Ciccarelli, Nicoletta (ORCID:0000-0002-7582-9142), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.
Published: 2015

47. Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine

Author: Belmonti, S, Lombardi, Francesca, Morandi, M, Fabbiani, Massimiliano, Tordini, G, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Montagnani, F., Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076), Belmonti, S, Lombardi, Francesca, Morandi, M, Fabbiani, Massimiliano, Tordini, G, Cauda, Roberto, De Luca, Andrea, Di Giambenedetto, Simona, Montagnani, F., Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), and Di Giambenedetto, Simona (ORCID:0000-0001-6990-5076)
Abstract: The 13-valent pneumococcal conjugate vaccine (PCV-13) is recommended for HIV-infected people, although its effectiveness in this population remains under evaluation. In this study we describe the development, optimization and analytical validation of an ELISA procedure to measure specific antibodies for the pneumococcal polysaccharide serotypes included in PCV13 vaccine, testing sera obtained from HIV-infected outpatients (n=30) who received the vaccine. The protocol followed the last version of WHO guidelines, based on the new standard 007sp, with the modification of employing Statens Serum Institut (SSI) antigens. We supplied the assay performance validation in terms of sensitivity, reproducibility, precision and accuracy. In addition we detailed optimal antigen-coating concentrations and ELISA conditions common to all 13 serotypes, suitable for laboratories performing these assays in order to standardize the method. Our procedure showed reproducibility and reliability, making it a valid alternative for evaluating the response to pneumococcal serotypes included in PCV13 vaccine.
Published: 2015

48. Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy

Author: Puttini, Camilla, Riccio, Maria Letizia, Redi, David, Tordini, Giacinta, Cenerini, Melissa, Romanello, Fulvia, De Luca, Andrea, Carmellini, Mario, Fossombroni, Vittorio, Cusi, Maria Grazia, Zanelli, Giacomo, De Luca, Andrea (ORCID:0000-0002-8311-6935), Puttini, Camilla, Riccio, Maria Letizia, Redi, David, Tordini, Giacinta, Cenerini, Melissa, Romanello, Fulvia, De Luca, Andrea, Carmellini, Mario, Fossombroni, Vittorio, Cusi, Maria Grazia, Zanelli, Giacomo, and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: notb available
Published: 2015

49. State of the Art of Dual Therapy in 2015

Author: Nozza, Silvia, Svicher, Valentina, Saracino, Annalisa, D'Ettorre, Gabriella, De Luca, Andrea, Maggiolo, Franco, Bonora, Stefano, di Biagio, Antonio, Rusconi, Stefano, Mussini, Cristina, De Luca, Andrea (ORCID:0000-0002-8311-6935), Nozza, Silvia, Svicher, Valentina, Saracino, Annalisa, D'Ettorre, Gabriella, De Luca, Andrea, Maggiolo, Franco, Bonora, Stefano, di Biagio, Antonio, Rusconi, Stefano, Mussini, Cristina, and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: not available
Published: 2015

50. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study

Author: Mussini, Cristina, Lorenzini, Patrizia, Cozzi Lepri, Alessandro, Lapadula, Giuseppe, Marchetti, Giulia, Nicastri, Emanuele, Cingolani, Antonella, Lichtner, Miriam, Antinori, Andrea, Gori, Andrea, Monforte, Antonella d'Arminio, Moroni, M., Andreoni, M., Angarano, G., Antinori, A., d'Arminio Monforte, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., von Schloesser, F., Viale, P., Castagna, A., Ceccherini Silberstein, F., Cozzi Lepri, A., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bonfanti, P., Bonora, S., Borderi, M., Capobianchi, M. R., Cingolani, A., Cinque, P., De Luca, Andrea, Di Biagio, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, Giordano, Maggiolo, F., Marchetti, G., Marcotullio, S., Monno, L., Quiros Roldan, E., Rusconi, S., Saracino, A., Cicconi, P., Fanti Galli, I., Lorenzini, P., Tavelli, A., Giacometti, A., Costantini, A., Mazzoccato, S., Santoro, C., Suardi, C., Vanino, E., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., E. Manconi, P., Piano, P., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Cassola, G., Viscoli, C., Alessandrini, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Guida, M. G., Gargiulo, M., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Cauda, R., Vullo, V., D'Avino, A., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Tebano, G., Cattelan, A., Sasset, L., Mura, M. S., De Luca, A., Rossetti, B., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Cingolani, Antonella (ORCID:0000-0002-3793-2755), Cauda, Roberto (ORCID:0000-0002-1498-4229), De Luca, Andrea (ORCID:0000-0002-8311-6935), Mussini, Cristina, Lorenzini, Patrizia, Cozzi Lepri, Alessandro, Lapadula, Giuseppe, Marchetti, Giulia, Nicastri, Emanuele, Cingolani, Antonella, Lichtner, Miriam, Antinori, Andrea, Gori, Andrea, Monforte, Antonella d'Arminio, Moroni, M., Andreoni, M., Angarano, G., Antinori, A., d'Arminio Monforte, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., von Schloesser, F., Viale, P., Castagna, A., Ceccherini Silberstein, F., Cozzi Lepri, A., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bonfanti, P., Bonora, S., Borderi, M., Capobianchi, M. R., Cingolani, A., Cinque, P., De Luca, Andrea, Di Biagio, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, Giordano, Maggiolo, F., Marchetti, G., Marcotullio, S., Monno, L., Quiros Roldan, E., Rusconi, S., Saracino, A., Cicconi, P., Fanti Galli, I., Lorenzini, P., Tavelli, A., Giacometti, A., Costantini, A., Mazzoccato, S., Santoro, C., Suardi, C., Vanino, E., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., E. Manconi, P., Piano, P., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Cassola, G., Viscoli, C., Alessandrini, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Guida, M. G., Gargiulo, M., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Cauda, R., Vullo, V., D'Avino, A., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Tebano, G., Cattelan, A., Sasset, L., Mura, M. S., De Luca, A., Rossetti, B., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Cingolani, Antonella (ORCID:0000-0002-3793-2755), Cauda, Roberto (ORCID:0000-0002-1498-4229), and De Luca, Andrea (ORCID:0000-0002-8311-6935)
Abstract: Background: In patients with HIV, immune reconstitution after antiretroviral therapy (ART) is often incomplete. We assessed the probability of patients reaching a CD4/CD8 ratio of 1 or more after the start of ART and its association with the onset of non-AIDS-defining events and death. Methods: We did an analysis of the ICONA cohort, which recruited treatment-naive patients with HIV in Italy. We included participants in the cohort who started ART, reached an undetectable viral load (≤80 copies per mL), and had a CD4/CD8 ratio of less than 0·8 at the time of an undetectable viral load. We defined ratio normalisation in patients as two consecutive values of 1 or more. We used Kaplan-Meier curves to estimate the cumulative probability of ratio normalisation. We then used Poisson regression models to identify factors independently associated with normalisation and with progression to non-AIDS-defining events or death. Findings: We included 3236 participants, enrolled between Jan 22, 1997, and Feb 25, 2013. At the start of ART, median CD4/CD8 ratio in our population was 0·39 (IQR 0·26-0·55). 458 (14%) patients reached a CD4/CD8 ratio of 1 or more; the estimated probability of normalisation was 4·4% (95% CI 3·7-5·2) by 1 year from baseline, 11·5% (10·2-13·0) by 2 years, and 29·4% (26·7-32·4) by 5 years. Factors associated with normalisation were high pre-ART CD4 cell counts, a high CD4/CD8 ratio at baseline, and negative cytomegalovirus serological findings. The incidence rate of non-AIDS-defining events for patients with a CD4/CD8 ratio of less than 0·30 (4·2 per 100 patient-years, 95% CI 3·4-5·3) was double that for those with a ratio of 0·30-0·45 (2·3, 2·1-2·5) or more than 0·45 (2·2, 1·7-2·9). A ratio of less than 0·30 was independently associated with an increased risk of non-AIDS-defining events or death compared with one of more than 0·45. Interpretation: Few patients had normalised CD4/CD8 ratios, even though they had viral suppression. Low ratios were associated
Published: 2015

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Publication Year Range

Publication Type

Database

Publisher

207 results on '"De Luca, Andrea (ORCID:0000-0002-8311-6935)"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources